) Medica. (formerly WellFirst Health)	INJ	IECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or no coverage review of any drug listed	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For	This is a large document, but you can search quickly and easily by clicking on th for you to type in the name of drug you want to locate. If you do not know the few letters of the	correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	Q2055	ABECMA	Idecabtagene vicleucel	Yes, through the Plan Pharmacy Services	ABECMA (Idecabtagene vicleucel)	ABECMA (Idecabtagene vicleucel)	See National Cov
Medical	J9264	ABRAXANE	paclitaxel protein bound	Yes, through the Plan Pharmacy Services	ABRAXANE (paciltaxel protein-bound particles)	ABRAXANE (paclitaxel protein bound)	See National Cov
Pharmacy	J3262	ACTEMRA (SC)	Itocilizuman	Yes, through Navitus. Restricted to (in at least consultation with an Rheumatology specialist with authorization.	ACTEMRA SC (tocilizumab)	ACTEMRA SC (tocilizumab)	Medicare covera
Medical	J3262	ACTEMRA (IV)	Itociliziiman	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with an Rheumatology specialist with authorization.	ACTEMRA IV (tocilizumab)	ACTEMRA IV (tocilizumab)	See National Cov
Pharmacy	J0800	ACTHAR GEL	Ironository corticotrinin injection	PHARMACY BENEFIT ONLY. Yes, through Navitus. Refer to members pharmacy benefit formulary for coverage.		ACTHAR GEL (repository corticotripin injection)	See National Cove
Medical	J0791	ADAKVEO	lcrizanlizumah-tmca	Yes, through the Plan Pharmacy Services. Restricted to an Hematology specialist with authorization.	ADAKVEO (crizanlizumab-tmca)	ADAKVEO (crizanlizumab)	Medicare covera
Medical	J9042	ADCETRIS	brentuximab vedotin	Yes, through the Plan Pharmacy Services	ADCETRIS (brentuximab vedotin)	ADCETRIS (brentuximab vedotin)	See National Cov
Medical	J9029	ADSTILADRIN	nadogaragene firadenovec-vncg	Yes, through the Plan Pharmacy Services.	ADSTILADRIN (nadogaragene firadenovec-vncg	ADSTILADRIN (nadogaragene firadenovec-vncg)	See National Cov
Medical	J7171	ADZYNMA	ADAMTS13, recombinant-krhn	Yes, through the Plan Pharmacy Services	ADZYNMA (ADAMTS13, recombinant-krhn)	ADZYNMA (ADAMTS13, recombinant-krhn)	MAPD Prior Auth
Medical	Q5150	AHZANTIVE	aflibercept	Yes, through the Plan Pharmacy Services	AHZANTIVE (aflibercept)	AHZANTIVE (aflibercept)	MAPD Prior Autho
	J1454	AKYNEZO		Yes, through the Plan Pharmacy Services	AKYNEZO (fosbetupitant/palonsetron)	AKYNEZO (fosbetupitant/palonosetron)	See National Cov
Medical	J1931	ALDURAZYME	laronidase	Yes, through the Plan Pharmacy Services. Restricted to (or in consultation with) medical geneticist or other prescriber specialized in the treatment of mucopolysaccharidosis with authorization.	ALDURAZYME (laronidase)	ALDURAZYME (laronidase)	MAPD Prior Auth
Medical	J9305	ALIMTA	pemetrexed	Yes, through the Plan Pharmacy Services	ALIMTA (pemetrexed)	ALMITA (pemetrexed)	See National Cov
Medical	J9057	ALIQOPA	copanlisib	Yes, through the Plan Pharmacy Services	ALIQOPA (copanlisib)	ALIQOPA (copanlisib)	See National Cov
Medical	J2469	ALOXI	palonosetron	EFFECTIVE 02/01/2023 No Prior Authorization is Required	ALOXI (palonosetron)		See National Cov
Medical	Q5126	ALYMSYS	bevacizumab	As of 03/01/2024: Zirabev is the preferred Bevacizumab product and does not require prior authorization. Avastin, Alymsys, Mvasi and Vegzelma prior authorization is required through the Plan Pharmacy Services. ***Prior authorization for bevacizumab is not required when used for ophtalmological indications.*** See the ALYMSYS (bevacizumab) Policy for a list of applicable ophthalmological diagnoses.	<u>ALYMSYS (bevacizumab)</u>	ALYMSYS (bevacizumab)	Medicare covera
Medical	J1426	AMONDYS	casimersen	None. Not Covered.	AMONDYS (casimersen)		MAPD Prior Auth
Medical	19999	AMTAGVI	lifileucel	Yes, through the Plan Pharmacy Services	AMTAGVI (lifleucel)	AMTAGVI (lifleucel)	MAPD Prior Auth
Medical	J0225	AMVUTTRA	viutisiran	Yes, through the Plan Pharmacy Services	AMVUTTRA (vutrisiran)	AMVUTTRA (vutisiran)	See National Cov
Medical	J9028	ΑΝΚΤΙVΑ	nogapendekin alfa inbakicept-pmln	Yes, through the Plan Pharmacy Services	Anktiva (nogapendekin alfa inbakicept-pmln)	Anktiva (nogapendekin alfa inbakicept-pmln)	MAPD Prior Auth
IVIedical	J7175, J7178, J7179, J7180, J7181, J7188, J7189, J7198, J7212	Antihemophilia Factor and Clotting Factors (Coagadex, RiaSTAP, Vonvendi, Corifact, Tretten, Obizur, Novoseven RT, Feiba NF,		Yes, through Dean Health Plan Utilization Management Department.			
		Sevenfact)	(recombinant), antiinhibitor coagulant complex, Coagulation factor VIIa (recombinant)-jncw)	Restricted to an Hematology specialist with authorization.	ANTIHEMOPHILIA FACTOR AND CLOTTING FACTORS	ANTIHEMOPHILIA FACTOR AND CLOTTING FACTORS	
Medical	J7182, J7183, J7185, J7186, J7187, J7190, J7192, J7204, J7205, J7207, J7208, J7209, J7210, J7211, J7214		(recombinant), antiinhibitor coagulant complex, Coagulation factor VIIa (recombinant)-jncw) (antihemophilic factor (recombinant), von Willebrand factor/coagulation factor VIII complex (human), antihemophilic factor (recombinant), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (recombinant), antihemophilic factor (recombinant),	Restricted to an Hematology specialist with authorization.	ANTIHEMOPHILIA FACTOR AND CLOTTING FACTORS	ANTIHEMOPHILIA FACTOR AND CLOTTING FACTORS	
Medical	J7190, J7192, J7204, J7205, J7207,	Sevenfact) Antihemophilic Factor VIII (Novoeight, Wilate, Xyntha, Alphanate, Humate-P, Hemofil M, Koate-DVI, Advate, Kogenate FS, Recombinate, Esperoct, Afstyla, Eloctate, Adynovate, Jivi, Nuwiq, Kovaltry, Altuviio) Antihemophilic Factor IX (Alphanine SD, Mononine,	(recombinant), antiinhibitor coagulant complex, Coagulation factor VIIa (recombinant)-jncw) (antihemophilic factor (recombinant), von Willebrand factor/coagulation factor VIII complex (human), antihemophilic factor (recombinant), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (recombinant), antihemophilic factor (recombinant), antihemophilic factor (recombinant), Antihemophilic factor (recombinant) glycol-peglated, antihemophilic factor (recombinant) single chain, antihemophilic factor (recombinant), antihemophilic factor (recombinant) pegylated, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) human, antihemophilic factor (recombinant) (coagulation Factor IX, coagulation Factor IX, factor IX complex, coagulation factor IX (recombinant), coagulation factor IX (recombinant), coagulation factor IX (recombinant),	Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to Hematology specialist with authorization.			
Medical	J7190, J7192, J7204, J7205, J7207, J7208, J7209, J7210, J7211, J7214 J7193, J7194, J7195, J7200, J7201,	Sevenfact) Antihemophilic Factor VIII (Novoeight, Wilate, Xyntha, Alphanate, Humate-P, Hemofil M, Koate-DVI, Advate, Kogenate FS, Recombinate, Esperoct, Afstyla, Eloctate, Adynovate, Jivi, Nuwiq, Kovaltry, Altuviio) Antihemophilic Factor IX (Alphanine SD, Mononine, Profilnine, Benefix, Ixinity, Rixubis,	(recombinant), antiinhibitor coagulant complex, Coagulation factor VIIa (recombinant)-jncw) (antihemophilic factor (recombinant), von Willebrand factor/coagulation factor VIII complex (human), antihemophilic factor (recombinant), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (recombinant), antihemophilic factor (recombinant), antihemophilic factor (recombinant), Antihemophilic factor (recombinant) glycol-peglated, antihemophilic factor (recombinant) single chain, antihemophilic factor (recombinant), antihemophilic factor (recombinant) pegylated, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) human, antihemophilic factor (recombinant) (coagulation Factor IX, coagulation Factor IX, factor IX complex, coagulation factor IX (recombinant), coagulation factor IX (recombinant), coagulation factor IX (recombinant), coagulation factor IX (recombinant), fc fusion protein, coagulation factor IX (recombinant), human, coagulation factor IX (recombinant), glycopegylated)	Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to Hematology specialist with authorization.	ANTIHEMOPHILIC FACTOR VIII	ANTIHEMOPHILIC FACTOR VIII.	
Medical Medical	J7190, J7192, J7204, J7205, J7207, J7208, J7209, J7210, J7211, J7214 J7193, J7194, J7195, J7200, J7201, J7202, J7203	Sevenfact) Antihemophilic Factor VIII (Novoeight, Wilate, Xyntha, Alphanate, Humate-P, Hemofil M, Koate-DVI, Advate, Kogenate FS, Recombinate, Esperoct, Afstyla, Eloctate, Adynovate, Jivi, Nuwiq, Kovaltry, Altuviio) Antihemophilic Factor IX (Alphanine SD, Mononine, Profilnine, Benefix, Ixinity, Rixubis, Alprolix, Idelvion, Rebinyn)	(recombinant), antiinhibitor coagulant complex, Coagulation factor VIIa (recombinant)-jncw) (antihemophilic factor (recombinant), von Willebrand factor/coagulation factor VIII complex (human), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (recombinant), antihemophilic factor (recombinant), antihemophilic factor (recombinant), antihemophilic factor (recombinant) glycol-peglated, antihemophilic factor (recombinant) pegylated, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) human, antihemophilic factor (recombinant) (coagulation Factor IX, coagulation Factor IX, factor IX complex, coagulation factor IX (recombinant), fo fusion protein, coagulation factor IX (recombinant), human, coagulation factor IX (recombinant), glycopegylated) motixafortide antihation factor IX (recombinant), human, coagulation factor IX (recombinant), human, coagulation factor IX (recombinant), coagulation factor IX (recombinant), human, coagulation	Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to Hematology specialist with authorization.	ANTIHEMOPHILIC FACTOR VIII.	ANTIHEMOPHILIC FACTOR VIII. ANTIHEMOPHILIC FACTOR IX. Aphexda ^m (motixafortide)	Medicare covera
Medical Medical Medical Medical	J7190, J7192, J7204, J7205, J7207, J7208, J7209, J7210, J7211, J7214 J7193, J7194, J7195, J7200, J7201, J7202, J7203	Sevenfact) Antihemophilic Factor VIII (Novoeight, Wilate, Xyntha, Alphanate, Humate-P, Hemofil M, Koate-DVI, Advate, Kogenate FS, Recombinate, Esperoct, Afstyla, Eloctate, Adynovate, Jivi, Nuwiq, Kovaltry, Altuviio) Antihemophilic Factor IX (Alphanine SD, Mononine, Profilnine, Benefix, Ixinity, Rixubis, Alprolix, Idelvion, Rebinyn) APHEXDA	(recombinant), antiinhibitor coagulant complex, Coagulation factor VIIa (recombinant)-jncw)(antihemophilic factor (recombinant), von Willebrand factor/coagulation factor VIII complex (human), antihemophilic factor (recombinant), antihemophilic factor/von Willebrand factor complex (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (human), antihemophilic factor (recombinant), antihemophilic factor (recombinant), antihemophilic factor (recombinant), Antihemophilic factor (recombinant) glycol-peglated, antihemophilic factor (recombinant) single chain, antihemophilic factor (recombinant) single chain, antihemophilic factor (recombinant) single chain, antihemophilic factor (recombinant) single chain, antihemophilic factor (recombinant) antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) pegylated-aucl, antihemophilic factor (recombinant) human, antihemophilic factor (recombinant)(coagulation Factor IX, coagulation Factor IX, factor IX complex, coagulation factor IX (recombinant), coagulation factor IX (recombinant), coagulation factor IX (recombinant), coagulation factor IX (recombinant), human, coagulation factor IX (recombinant), glycopegylated)motixafortidealpha-1-proteinase inhibitor (human)	Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to an Hematology specialist with authorization. Yes, through Dean Health Plan Utilization Management Department. Restricted to Hematology specialist with authorization. Yes, through the Plan Pharmacy Services Yes, through the Plan Pharmacy Services. Restricted to an Pulmonology	ANTIHEMOPHILIC FACTOR VIII. ANTIHEMOPHILIC FACTOR IX. Aphexda ^m (motixafortide)	ANTIHEMOPHILIC FACTOR VIII. ANTIHEMOPHILIC FACTOR IX. Aphexda ^m (motixafortide)	Medicare covera

MAPD
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
onal Coverage DeterminatSee National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictic
e coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
e coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO.
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
e coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals
rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions

Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO

Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals

re coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals

ions WI, IL, MO
is WI, IL, MO.

International problem International problem International problem 1					1		1	· · · · · · · · · · · · · · · · · · ·
Instruction Instruction <thinstruction< th=""> <thinstruction< th=""></thinstruction<></thinstruction<>			IN	JECTABLE MEDICINES	SEARCH TIPS:			
Ideal Ideal Ideal Ideal Ideal Prote Automatoria Prote Automatoria Ideal Allorena Allorena Ideal			are covered, not covered, or no coverage review of any drug liste	ot yet reviewed and whether a prior authorization is required. For ed as not covered, please complete the Exception to Coverage form website for medical submit to the Plan Pharmacy Services and for	This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the	correct spelling, you can start your search by entering just the first		
M MAC MAC <thmac< th=""> <thmac< th=""> <thmac< th=""></thmac<></thmac<></thmac<>	Benefit		Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
And And <td>Medical</td> <td>C9072</td> <td>ASCENIV (IVIG) - non-preferred</td> <td></td> <td></td> <td>ASCENIV (IVIG)</td> <td>ASCENIV (IVIG)</td> <td>See National C</td>	Medical	C9072	ASCENIV (IVIG) - non-preferred			ASCENIV (IVIG)	ASCENIV (IVIG)	See National C
interm interm interm interm interm interm No. Sintern Sintern<	Medical	19999	AUCATZYL	Obecabtagene Autoleucel - Obe-cel	Yes, through the Plan Pharmacy Services	AUCATZYL (Obecabtagene Autoleucel - Obe-cel)	AUCATZYL (Obecabtagene Autoleucel - Obe-cel)	MAPD Prior A
NAMSintherSi	Medical	J9292	AXTLE	pemetrexed	Yes, through the Plan Pharmacy Services	AXTLE (pemetrexed)	AXTLE (pemetrexted)	
num num <td>Medical</td> <td>J9035</td> <td>AVASTIN</td> <td></td> <td>not require prior authorization. Avastin, Alymsys, Mvasi and Vegzelma prior authorization is required through the Plan Pharmacy Services. ***Prior authorization for bevacizumab is not required when used for ophtalmological indications.*** See the ALYMSYS (bevacizumab) Policy</td> <td>AVASTIN (bevacizumab)</td> <td>AVASTIN (bevacizumab)</td> <td>Medicare cov</td>	Medical	J9035	AVASTIN		not require prior authorization. Avastin, Alymsys, Mvasi and Vegzelma prior authorization is required through the Plan Pharmacy Services. ***Prior authorization for bevacizumab is not required when used for ophtalmological indications.*** See the ALYMSYS (bevacizumab) Policy	AVASTIN (bevacizumab)	AVASTIN (bevacizumab)	Medicare cov
Index	Medical	Q5121	AVSOLA - non-preferred	linfliximah-axxo		<u>AVSOLA (infliximab-axxq)</u>	<u>AVSOLA (infliximab-axxq)</u>	See National (
Note And And <td>Medical</td> <td>19999</td> <td>AVZIVI</td> <td>bevacizumab</td> <td>Yes, through the Plan Pharmacy Services</td> <td><u>AVZIVI (bevacizumab)</u></td> <td><u>AVZIVI (bevacizumab)</u></td> <td></td>	Medical	19999	AVZIVI	bevacizumab	Yes, through the Plan Pharmacy Services	<u>AVZIVI (bevacizumab)</u>	<u>AVZIVI (bevacizumab)</u>	
No 10No 10No 10No 10No 10No 1010No 10No 10No 10No 10No 10No 10No 1011No 10No 10No 10No 10No 10No 10No 10No 10110No 	Medical	A9590	AZEDRA	iobenguane I-131	Yes, through the Plan Pharmacy Services	AZEDRA (iobenguane-I-131)	AZEDRA (iobenguane I-131)	See National
Number Sub Sub Sub Sub Sub Subs Subs <td< td=""><td>Medical</td><td>J9023</td><td>BAVENCIO</td><td>avelumab</td><td>Yes, through the Plan Pharmacy Services</td><td>BAVENCIO (avelumab)</td><td>BAVENCIO (avelumab)</td><td></td></td<>	Medical	J9023	BAVENCIO	avelumab	Yes, through the Plan Pharmacy Services	BAVENCIO (avelumab)	BAVENCIO (avelumab)	
No.No	Medical	J9032	BELEODAQ	IDEUDONIAL		<u>BELEODAQ (belinostat)</u>	<u>BELEODAQ (belinostat)</u>	Medicare cov
NoteNo	Medical	J9036	BELRAPZO	bendamustine	Yes, through the Plan Pharmacy Services	BELRAPZO (bendamustine)	BELRAPZO (bendamustine)	See National (
NATH SPACE RVST(M RVST(M) RVST(M) <th< td=""><td>Medical</td><td>J9034</td><td>BENDEKA</td><td>bendamustine</td><td>Yes, through the Plan Pharmacy Services</td><td>BENDEKA (bendamustine)</td><td>BENDEKA (bendamustine)</td><td>See National</td></th<>	Medical	J9034	BENDEKA	bendamustine	Yes, through the Plan Pharmacy Services	BENDEKA (bendamustine)	BENDEKA (bendamustine)	See National
Name Kall	Medical	J0490	BENLYSTA (IV)	belimumab	consultation with) a Rheumatology, Dermatology, or Nephrology	BENLYSTA IV (belimumab)	BENLYSTA IV (belimumab)	Medicare cov
NoteNoteNoteNoteNoteNoteNoteNoteNameSPACeSecond	Pharmacy	J0490	BENLYSTA (SC)		Rheumatology, Dermatology, or Nephrology specialists with	<u>BENLYSTA SC (belimumab)</u>	<u>BENLYSTA SC (belimumab)</u>	Medicare cov
No. No. No. No. No. No. No. No. No.11 19.1000 10.707 10.20000 <td>Medical</td> <td>J0179</td> <td>BEOVU</td> <td>brolucizumab-dbll</td> <td>EFFECTIVE 07/01/2024. Yes, through the Plan Pharmacy Services</td> <td>BEOVU (brolucizumab-dbll)</td> <td>BEOVU (brolucizumab-dbll)</td> <td>MAPD Prior Au</td>	Medical	J0179	BEOVU	brolucizumab-dbll	EFFECTIVE 07/01/2024. Yes, through the Plan Pharmacy Services	BEOVU (brolucizumab-dbll)	BEOVU (brolucizumab-dbll)	MAPD Prior Au
Index	Medical	J9229	BESPONSA	inotuzumab ozogamicin	Yes, through the Plan Pharmacy Services	BESPONSA (inotuzumab ozogamicin)	BESPONSA (inotuzumab ozogamicin)	See National
Altical and and billingAnd an	Medical	J1414	BEQVEZ	fidanacogene elaparvovec-dzkt	Yes, through the Plan Pharmacy Services	Beqvez (fidanacogene elaparvovec-dzkt)	<u>Beqvez (fidanacogene elaparvovec-dzkt)</u>	MAPD Prior A
Indiancy Indiance Indiance <th< td=""><td>Medical</td><td>J1556</td><td></td><td>immune globulin (bivigam)</td><td>Yes, through the Plan Pharmacy Services</td><td>BIVIGAM (IVIG)</td><td>BIVIGAM (IVIG)</td><td>MAPD Prior A</td></th<>	Medical	J1556		immune globulin (bivigam)	Yes, through the Plan Pharmacy Services	BIVIGAM (IVIG)	BIVIGAM (IVIG)	MAPD Prior A
INDERSIDANTINTERCANT <td>Medical</td> <td>19999</td> <td>BIZENGRI</td> <td>zenocutuzumab-zbco</td> <td>Yes, through the Plan Pharmacy Services</td> <td>BIZENGRI (zenocutuzumab-zbco)</td> <td>BIZENGRI (zenocutuzumab-zbco)</td> <td>MAPD Prior A</td>	Medical	19999	BIZENGRI	zenocutuzumab-zbco	Yes, through the Plan Pharmacy Services	BIZENGRI (zenocutuzumab-zbco)	BIZENGRI (zenocutuzumab-zbco)	MAPD Prior A
MercialMode <th< td=""><td>Medical</td><td>Q5152</td><td>BKEMV</td><td>eculizumab</td><td>Yes, through the Plan Pharmacy Services</td><td><u>BKEMV (eculizumab)</u></td><td></td><td>MAPD Prior A</td></th<>	Medical	Q5152	BKEMV	eculizumab	Yes, through the Plan Pharmacy Services	<u>BKEMV (eculizumab)</u>		MAPD Prior A
index index <th< td=""><td>Medical</td><td>J9039</td><td>BLINCYTO</td><td>blinatumomab</td><td></td><td>BLINCYTO (blinatumomab)</td><td>BLINCYTO (blinatumomab)</td><td>Medicare cov</td></th<>	Medical	J9039	BLINCYTO	blinatumomab		BLINCYTO (blinatumomab)	BLINCYTO (blinatumomab)	Medicare cov
Index Index <th< td=""><td>Medical</td><td>J9044</td><td>BORTEZOMIB</td><td></td><td>Yes, through the Plan Pharmacy Services</td><td>BORTEZOMIB_</td><td>BORTEZOMIB</td><td>Medicare cov</td></th<>	Medical	J9044	BORTEZOMIB		Yes, through the Plan Pharmacy Services	BORTEZOMIB_	BORTEZOMIB	Medicare cov
Image: Note of the state o	Medical	J9054	BORUZU	bortezomib	Yes, through the Plan Pharmacy Services	BORTEZOMIB	BORTEZOMIB	
Image: Notice Notic Notice Notice<	Medical	J0585	вотох	onabotulinumtoxin	No prior authorization is required.	BOTOX (onabotulinumtoxinA)		MAPD Prior A
A controlA control <td>Medical</td> <td>Q2054</td> <td>BREYANZI</td> <td>lisocabtagene maraleucel</td> <td>Yes, through the Plan Pharmacy Services</td> <td>BREYANZI (lisocabtagene maraleucel)</td> <td>BREYANZI (lisocabtagene maraleucel)</td> <td>See National</td>	Medical	Q2054	BREYANZI	lisocabtagene maraleucel	Yes, through the Plan Pharmacy Services	BREYANZI (lisocabtagene maraleucel)	BREYANZI (lisocabtagene maraleucel)	See National
Medical DS67, S014 BRINE URA cerliponase alfa consultation with) a specialist who treats the Late infantile Ceroid BRINE URA (cerliponase alfa) BRINE URA (cerliponase alfa) Medicare of the certification Medical 0524 S024 spool ranibizumab) ranibizumab ves, through the Plan Pharmacy Services SVOVIZ (canibizumab) SVOVIZ (canibizumab) SVOVIZ (canibizumab) MAPO Prior Medical Jo43 cABZITAXEL cabzitaxel (levtana) sextence <	Medical	J2329	BRIUMVI	ublituximab-xiiy	Yes, through the Plan Pharmacy services.	<u>BRIUMVI (ublituximab-xiiy)</u>	BRIUMVI (ublituximab-xiiy)	Medicare cov
Image: And the state Image: And the state <th< td=""><td>Medical</td><td>J0567, C9014</td><td>BRINEURA</td><td></td><td>consultation with) a specialist who treats the Late infantile Ceroid</td><td>BRINEURA (cerliponase alfa)</td><td>BRINEURA (cerliponase alfa)</td><td>Medicare cov</td></th<>	Medical	J0567, C9014	BRINEURA		consultation with) a specialist who treats the Late infantile Ceroid	BRINEURA (cerliponase alfa)	BRINEURA (cerliponase alfa)	Medicare cov
	Medical	Q5124	BYOOVIZ	ranibizumab	Yes, through the Plan Pharmacy Services	BYOOVIZ (ranibizumab)	BYOOVIZ (ranibizumab)	MAPD Prior A
Medical C2056 CARVYKTI (ciltacabtagene autoleucel) CARVYKTI (ciltacabtagene autoleucel) See Nation	Medical	J9043	CABZITAXEL	Cabazitaxel (Jevtana)	Yes, through the Plan Pharmacy Services	CABAZITAXEL (Jevtana)	CABZITAXEL (Jevtana)	See National
	Medical	C2056	CARVYKTI	ciltacabtagene autoleucel	Yes, through the Plan Pharmacy Services	CARVYKTI (ciltacabtagene autoleucel)	CARVYKTI (ciltacabtagene autoleucel)	See National

MAPD al Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs e coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO ior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs e coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO onal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO

ns WI, IL, MO.
ns WI, IL, MO
ns WI, IL, MO.
ns WI, IL, MO

	Madica					1	
	(formerly WellFirst Health)	IN.	JECTABLE MEDICINES	SEARCH TIPS:		-	
	Updated: 05/01/2025	are covered, not covered, or no coverage review of any drug lister	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For d as not covered, please complete the Exception to Coverage form vebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the few letters of the	correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J3392	CASGEVY	exagamglogene autotemcel	Yes, through the Plan Pharmacy Services	CASGEVY (exagamglogene autotemcel)	CASGEVY (exagamglogene autotemcel)	MAPD Prior Au
Medical	J1786	CEREZYME	imiglucerase (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Gaucher DX with authorization.	CEREZYME (imiglucerase) (Intravenous)	CEREZYME (imiglucerase) (Invtravenous)	Medicare cove
Medical	Q5128	CIMERLI	ranibizumab	Yes, through the Plan Pharmacy Services	<u>CIMERLI (ranibizumab)</u>	<u>CIMERLI (ranibizumab)</u>	MAPD Prior Au
Pharmacy	J0717	CIMZIA	Icertolizumah negol	PHARMACY BENEFIT ONLY. Verify prior authorization requirements by accessing the members formulary.		<u>CIMZIA (certolizumab pegol)</u>	
Medical	J2786	CINQAIR	Irocliziiman	Yes, through the Plan Pharmacy Services. Restricted to a Pulmonology, Allergy, and Immunology specialist with authorization.	<u>CINQAIR (reslizumab)</u>	<u>CINQAIR (reslizumab)</u>	See National Co
Medical	J1932	CIPLA	lanreotide depot	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Endocrinologist, Oncologist, or gastroenterologist specialist with authorization.	<u>CIPLA (lanreotide depot)</u>	<u>CIPLA (lanreotide depot)</u>	MAPD Prior Au
Medical	J9286	COLUMVI	glofitamab-gxbm	Yes, through the Plan Pharmacy Services	<u>COLUMVI™ (glofitamab-gxbm)</u>	<u>COLUMVI™ (glofitamab-gxbm)</u>	See National C
Medical	J1448	COSELA	trilaciclib	Yes, through the Plan Pharmacy Services	COSELA (trilaciclib)	COSELA (trilaciclib)	See National C
Medical	J3247	COSENTYX IV	secukinumab	Yes, through the Plan Pharmacy Services	COSENTYX IV (secukinumab)	COSENTYX IV (secukinumab)	MAPD Prior Au
Medical	J0584	CRYSVITA	burosumab	Yes, through the Plan Pharmacy Services. Restricted to Endocrinologist, Nephrologist, Medical Geneticist, or Specialist experienced in treatment of Metabolic Bone Disorders with authorization.	<u>CRYSVITA (burosumab)</u>	<u>CRYSVITA (burosumab)</u>	Medicare cove
Medical	J1555	CUVITRU (SCIG), IMMUNE GLOBULIN	immune globulin (cuvitru)	Yes, through the Plan Pharmacy Services	<u>CUVITRU (SCIG)</u>	<u>CUVITRU (SCIG)</u>	MAPD Prior Au
Medical	J9308	CYRAMZA	ramucirumab	Yes, through the Plan Pharmacy Services	CYRAMZA (ramucirumab)	CRYRAMZA (ramucirumab)	See National C
Medical	J9348	DANYELZA	naxitamab	Yes, through the Plan Pharmacy Services	DANYELZA (naxitamab)	DANYELZA (naxitamab)	See National C
Medical	J9145	DARZALEX	daratumumab	Yes, through the Plan Pharmacy Services	DARZALEX (daratmumab)	DARZALEX (daratumumab)	See National C
Medical	19999	DATROWAY	datopotamab deruxtecan-dlnk	Yes, through the Plan Phamacy Services	DATROWAY (datopotamab deruxtecan-dlnk)	DATROWAY (datopotamab deruxtecan-dlnk)	
Medical	J9144, C9062	DARZALEX FASPRO	daratumumab/hyaluronidase-fihj	Yes, through the Plan Pharmacy Services	DARZALEX FASPRO (daraumumab/hyaluronidase-fihj)	DARZALEX FASPRO (daratumumab/hyaluronidase-fihj)	See National C
Medical	J0589	DAXXIFY	daxibotulinumtoxinA	None. Please see attached policy for criteria.	DAXXIFY [®] (daxibotulinumtoxinA)		MAPD Prior Au
Medical	J7318	DUROLANE - non-preferred	sodium hyaluronate	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred product. Coverage of DUROLANE requires a failed trial of a preferred product. Prior authorization is required through the Plan Pharmacy Services and is restricted to a Rheumatology, Orthopedic, Sports Medicine, or Pain Medicine specialist with authorization.	<u>DUROLANE (sodium hyaluronate)</u>	<u>DUROLANE (sodium hyaluronate)</u>	See National Co
Medical	J0586	DYSPORT	abobotulinumtoxinA	No prior authorization is required.	DYSPORT (abobotulinumtoxinA)		See National Co
Medical	J9063	ELAHERE	mirvetuximab soravtansine-gynx	Yes, through the Plan Pharmacy Services	ELAHERE (mirvetuximab soravtansine-gynx)	ELAHERE (mirvetuximab soravtansine-gynx)	MAPD Prior Au
Medical	J1743	ELAPRASE	idursulfase (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Mucopolysaccharidosis II with authorization.	ELAPRASE (idursulfase)	ELAPRASE (idursulfase)	Medicare cove
Medical	J1413	ELEVIDYS	delandistrogene moxeparvovec-rokl	None. Not Covered	ELEVIDYS (delandistrogene moxeparvovec-rokl)		
Medical	J3060	ELELYSO	taliglucerase alfa (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Gaucher 1 DX with authorization.	ELELYSO (taliglucerase alfa)	ELELYSO (taliglucerase alfa)	Medicare cove
Medical	J2508	ELFABRIO	pegunigalsidase-alfa-ixwj	Yes, through the Plan Pharmacy Services	<u>ELFABRIO® (pegunigalsidase alfa-iwxj)</u>	<u>ELFABRIO® (pegunigalsidase alfa-iwxj)</u>	MAPD Prior Au
Medical	J1323	ELREXIFO	elranatamab-bcmm	Yes, through the Plan Pharmacy Services	<u>ELREXIFO™ (elranatamab-bcmm)</u>	ELREXIFO™ (elranatamab-bcmm)	MAPD Prior Au
Medical	J9269	ELZONRIS	tagraxofusp-erzs	Yes, through the Plan Pharmacy Services	ELZONRIS (tagraxofusp-erzs)	ELZONRIS (tagraxofusp-erzs)	MAPD Prior Au
Medical	J9176	EMPLICITI	elotuzumab	Yes, through the Plan Pharmacy Services	EMPLICITI (elotuzumab)	EPMLICITI (elotuzumab)	MAPD Prior Au

MAPD r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction al Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs al Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO nal Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

ns WI, IL, MO.	

	(formerly WellFirst Health)	INJ	JECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or not covered, or not coverage review of any drug listed	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For d as not covered, please complete the Exception to Coverage form vebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	This is a large document, but you can search quickly and easily by clicking on for you to type in the name of drug you want to locate. If you do not know the few letters of the	e correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J3590	ENCELTO	revakinagene taroretcel-lwey	EFFECTIVE 06/01/2025. Yes, through the Plan Pharmacy Services	Coming Soon	<u>Coming Soon</u>	
Medical	J9358	ENHERTU	fam-trastuzumab deruxtecan-nxki	Yes, through the Plan Pharmacy Services	ENHERTU (fam-trastuzumab deruxtecan-nxki)	ENHERTU (fam-trastuzumab deruxtecan-nxki)	MAPD Prior A
Medical	J1302	ENJAYMO	sutimlimab	Yes, through the Plan Pharmacy Services	ENJAYMO (sutimlimab-jome)	<u>ENJAYMO (sutimlimab-jome)</u>	MAPD Prior A
Medical	C9399, J3590	ENSPRYNG	satralizumab-mwge	Yes, Through the Plan Pharmacy Services	ENSPRYNG [®] (satralizumab-mwge)	ENSPRYNG [®] (satralizumab-mwge)	MAPD Prior A
Medical	J3380	ENTYVIO	vedolizumab	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Gastroenterology specialists with authorization.	ENTYVIO (vedolizumab)	<u>ENTYVIO (vedolizumab)</u>	MAPD Prior Au
Medical	Q5149	ENZEEVU	aflibercept	Yes, through the Plan Pharmacy Services.	ENZEEVU (aflibercept)	ENZEEVU (aflibercept)	
Medical	J9321	EPKINLY	epcoritamab-bysp	Yes, through the Plan Pharmacy Services	<u>EPKINLY™ (epcoritamab-bysp)</u>	<u>EPKINLY™ (epcoritamab-bysp)</u>	MAPD Prior A
Medical	J0885	EOPGEN	epoetin alfa, (for non-esrd use)	As of 01/01/2023: Retacrit is the preferred Epoetin Alfa products and does not require prior authorization. Epogen and Procrit prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria.	<u>EPOGEN (epoetin-alfa)</u>	EPOGEN (epoetin alpha)	MAPD Prior A
Medical	Q5151	EPYSQLI	eculizumab	Yes, through the Plan Pharmacy Services	EPYSQLI (eculizumab)	EPYSQLI (eculizumab)	MAPD Prior A
Medical	J9055	ERBITUX	cetuximab	Yes, through the Plan Pharmacy Services	ERBITUX (cetuximab)	ERBITUX (cetuximab)	MAPD Prior A
Medical	J7323	EUFLEXXA - non-preferred	sodium hyaluronate, 1%	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred product. Coverage of EUFLEXXA requires a failed trial of a preferred product. Prior authorization is required through the Plan Pharmacy Services and is restricted to a Rheumatology, Orthopedic, Sports Medicine, or Pain Medicine specialist with authorization.	EUFLEXXA (sodium hyaluronate, 1%)	EUFLEXXA (sodium hyaluronate, 1%)	MAPD Prior Au
Medical	J3111	EVENITY	romosozumab-aqqg	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Endocrinology or Rheumatology specialists with authorization.	<u>EVENITY (romosozumab-aqqg)</u>	EVENITY (romosozumab)	MAPD Prior A
Medical	J1305	EVKEEZA	evinacumab	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Cardiologist, Lipidologist, or Endocrinologist specialist with authorization.	EVKEEZA (evinacumab)	EVKEEZA (evinacumab)	MAPD Prior A
Pharmacy		EVRYSDI	risdiplam	Yes, through Navitus. Restricted to a pediatric neurologist at a Muscular Dystrophy Association care center with authorization.		EVRYSDI (risdiplam)	
Medical	J1428	EXONDYS 51	eteplirsen	None. Not Covered.	EXONDYS 51 (eteplirsen)		
Medical	J0178	EYLEA	aflibercept	EFFECTIVE 07/01/2024. Yes, through the Plan Pharmacy Services	EYLEA (afilbercept)	EYLEA (afilbercept)	MAPD Prior Au
Medical	J0177	EYLEA HD	aflibercept	EFFECTIVE 07/01/2024. Yes, through the Plan Pharmacy Services	EYLEA HD (afilbercept)	EYLEA HD (afilbercept)	MAPD Prior Au
Medical	J0180	FABRYZYME	agalsidase	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a medical geneticist or other prescriber specialized in the treatment of Fabry DX with authorization.	FABRYZYME (agalsidase)	FABRYZYME (agalsidase)	MAPD Prior A
Medical	J0517	FASENRA	benralizumab	Yes, through the Plan Pharmacy Services. Restricted to Pulmonology, Allergy, or Immunology specialists with authorization.	FASENRA (benralizumab)	FASENRA (benralizumab)	MAPD Prior Au
Medical	Q0138, Q0139	FERAHEME - preferred	ferumoxytol	As od 08/01/2022: VENOFER, INFED, FERRLECIT, and FERAHEME are the preferred parenteral iron products and do not require prior authorization. INJECTAFER, MONOFERRIC, TRIFERIC, and TRIFERIC AVNU are the non-preferred parenteral iron products and prior authorization is required through the Plan Pharmacy Services with authorization.			MAPD Prior A
Medical	J2916	FERRLECIT - preferred	sodium ferric gluconate complex	As of 08/01/2022: VENOFER, INFED, FERRLECIT, and FERAHEME are the preferred parenteral iron products and do not require prior authorization. INJECTAFER, MONOFERRIC, TRIFERIC, and TRIFERIC AVNU are the non-preferred parenteral iron products and prior authorization is required through the Plan Pharmacy Services with authorization.			MAPD Prior A
Medical	J1744	FIRAZYR	icatibant	Yes, through the Plan Pharmacy Services	FIRAZYR [®] (icatibant)	<u>FIRAZYR® (icatibant)</u>	MAPD Prior A
Medical	J1572	FLEBOGAMMA/FLEBOGAMMA DII (IVIG), IMMUNE GLOBULIN	F flebogamma	Yes, through the Plan Pharmacy Services	FLEBOGAMMA/FLEBOGAMMA DIF (IVIG)	FLEBOGAMMA/FLEBOGAMMA DIF (IVIG)	MAPD Prior A
Medical	Q5108	FULPHILA	pegfilgrastim-jmbd	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	FULPHILA (pegfligrastim-jmbd)	FULPHILA (pegfilgrastim-jmbd)	MAPD Prior A
Medical	J0641	FUSILEV	levoleucovorin	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Oncologist specialist with authorization.	<u>FUSILEV (levoleucovorin)</u>	<u>FUSILEV (levoleucovorin)</u>	MAPD Prior A
Medical	J9331	FYARRO	sirolimus albumin-bound	Yes, through the Plan Pharmacy Services	FYARRO (sirolimus albumin-bound)	FYARRO (sirolimus albumin-bound)	MAPD Prior A

MAPD rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO. r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO. rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO ior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

is WI, IL, MO.	
is WI, IL, MO	

s WI, IL, MO.
s WI, IL, MO.

) Medica . (formerly WellFirst Health)	IN.	IECTABLE MEDICINES	<u>SEARCH TIPS:</u>			
	Updated: 05/01/2025	are covered, not covered, or no coverage review of any drug listed	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For d as not covered, please complete the Exception to Coverage form vebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	t This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the few letters of the	correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	Q5130	FYLNETRA - non-preferred	pegfilgrastim-pbbk	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	<u>FYLNETRA (pegfilgrastim-pbbk)</u>	<u>FYLNETRA (pegfilgrastim-pbbk)</u>	MAPD Prior Au
Medical	J9210	GAMIFANT	emapalumab-lzsg	Yes, through the Plan Pharmacy Services	GAMIFANT [®] (emapalumab-lzsg)	GAMIFANT [®] (emapalumab-Izsg)	MAPD Prior Au
Medical	J1569	GAMMAGARD (SCIG), IMMUNE GLOBULIN	immune globulin, (gammagard liquid)	Yes, through the Plan Pharmacy Services	<u>GAMMAGARD (SCIG)</u>	<u>GAMMAGARD (SCIG)</u>	MAPD Prior Au
Medical	J1557	GAMMAPLEX (IVIG), IMMUNE GLOBULIN	immune globulin (gammaplex liquid)	Yes, through the Plan Pharmacy Services.	<u>GAMMAPLEX (IVIG)</u>	<u>GAMMAPLEX (IVIG)</u>	MAPD Prior Au
Medical	J1561	GAMUNEX-C/GAMMAKED (SCIG), IMMUNE GLOBULIN	gamunex injection	Yes, through the Plan Pharmacy Services	GAMUNEX-C/GAMMAKED (SCIG)	GAMUNEX-C/GAMMAKED (SCIG)	MAPD Prior Au
Medical	J9301	GAZYVA	obinutuzumab	Yes, through the Plan Pharmacy Services	GAZYVA (obinutuzumab)	GAZYVA (obinutuzumab)	MAPD Prior Au
Medical	J7326	GEL-ONE - non-preferred	hyaluronate sodium	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>GEL-ONE (hyaluronate sodium)</u>	MAPD Prior Au
Medical	J7328	GELSYN-3 - non-preferred	hyaluronate sodium	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>GELSYN-3 (hyaluronate sodium)</u>	MAPD Prior Au
Medical	J7320	GENVISC 850 - non-preferred	hyaluronan or derivitive	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>GENVISC 850 (hyaluronate or derivative)</u>	MAPD Prior Au
Medical	J0223	GIVLAARI	givosiran	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Hematologist or specialist with expertise in diagnosis and management of AHP with authorization.	<u>GIVLAARI (givosiran)</u>	<u>GIVLAARI (givosiran)</u>	MAPD Prior Au
Medical	J0257	GLASSIA	alpha-1-proteinase inhibitor (human)	Yes through the Plan Pharmacy Services. Restricted to an Pulmonology specialist with authorization.	GLASSIA (alpha-1-proteinase inhibitor)	GLASSIA (alpha-1-proteinase inhibitor)	MAPD Prior A
Medical	J1447	GRANIX	tbo-filgrastim	Yes, through the Plan Pharmacy Services	<u>GRANIX (tbo-filgrastim)</u>	<u>GRANIX (tbo-filgrastim)</u>	MAPD Prior Au
Medical	J1411	HEMGENIX	etranacogene dezaparvovec-drlb	Yes through the Plan Pharmacy Services	HEMGENIX (etranacogene dezaparvovec-drlb)	HEMGENIX (etranacogene dezaparvovec-drlb)	MAPD Prior Au
Pharmacy	J7170	HEMLIBRA	emicizumab	Yes, through Navitus. Refer to members pharmacy benefit formulary for coverage.		HEMLIBRA (emicizumab)	
Medical	J9248	ΗΕΡΖΑΤΟ	melphalan hydrochloride	EFFECTIVE 10/01/2024. Yes, through the Plan Pharmacy Services	<u>Hepzato (melphalan hydrochloride)</u>	<u>Hepzato™ (melphalan hydrochloride)</u>	MAPD Prior Au
Medical	J9355	HERCEPTIN	trastuzumab injection	Herzuma and Trazimera are the preferred Trastuzumab products and do not require prior authorization. Herceptin, Ogivri, Kanjinti and Ontruzant, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.		HERCEPTIN (trastuzumab injection)	MAPD Prior Au
Medical	J9356	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Yes, through the Plan Pharmacy Services	HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk)	HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk)	MAPD Prior Au
Medical	Q5146	HERCESSI	trastuzumab	Yes, through the Plan Pharmacy Services	HERCESSI (trastuzumab)	HERCESSI (trastuzumab)	
Medical	Q5113	HERZUMA	trastuzumab-pkrb	Herzuma and Trazimera are the preferred Trastuzumab products and do not require prior authorization. Herceptin, Ogivri, Kanjinti and Ontruzant, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.	HERZUMA (trastuzumab-pkrb)	HERZUMA (trastuzumab-pkrb	MAPD Prior Au
Medical	J1559	HIZENTRA (SCIG), IMMUNE GLOBULIN	immune globulin (hizentra)	Yes, through the Plan Pharmacy Services	<u>HIZENTRA (SCIG)</u>	<u>HIZENTRA (SCIG)</u>	MAPD Prior Au
Medical	J7321	HYALGAN - preferred	hyaluronate or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria			MAPD Prior Au
Medical	J9351	HYCAMTIN	topotecan	IV dosage form does not require PA Oral dosage form requires PA - Restricted to Oncologists with authorization through the Plan Pharmacy Services.		HYCAMTIN (topotecan)	MAPD Prior A
L	I		1	1	1		_1

MAPD r Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs ior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO. rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions

ns WI, IL, MO	
ns WI, IL, MO	

				-		_	
	(formerly WellFirst Health)	IN	JECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or no coverage review of any drug liste	ing of the most commonly prescribed drugs under the medical benefit ot yet reviewed and whether a prior authorization is required. For ed as not covered, please complete the Exception to Coverage form website for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	t This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the few letters of the	e correct spelling, you can start your search by entering just the first		
Benefit		Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical		HYMOVIS - preferred	hyaluronan	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria	HYMOVIS (hyaluronan)		MAPD Prior Authorization based on National Coverage Determination (N
Medical	J3590	HYMPAVZI	marstacimab-hncq	Yes, through the Plan Pharmacy Services.	<u>HYMPAVZI (marstacimab-hncq)</u>	<u>HYMPAVZI (marstacimab-hncq)</u>	
Medical	J1575	HYQVIA (SCIG), IMMUNE GLOBULIN	immune globulin (hyqvia)	Yes, through the Plan Pharmacy Services	HYQVIA (SCIG)	<u>HYQVIA (SCIG)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J3245	ILUMYA	tildrakizumab-asmn	Yes, through the Plan Pharmacy Services	ILUMYA [®] (tildrakizumab-asmn)	ILUMYA® (tildrakizumab-asmn)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	J9026	IMDELLTRA	tarlatamab-dlle	Yes, through the Plan Pharmacy Services	Imdelltra™ (tarlatamab-dlle)_	Imdelltra™ (tarlatamab-dlle)	MAPD Prior Authorization based on National Coverage Determinatio
Medical	J9173	IMFINZI	durvalumab	Yes, through the Plan Pharmacy Services	IMFINZI (durvalumab)	IMFINZI (durvalumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J9347	IMJUDO	tremelimumab-actl	Yes, through the Plan Pharmacy Services	IMJUDO (tremelimumab-actl)	IMJUDO (tremelimumab-actl)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J9325	IMLYGIC	talimogene laherparepvec	Yes, through the Plan Pharmacy Services	IMLYGIC (talimogene laherparepvec)	IMLYGIC (talimogene laherparepvec)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J3590	IMULDOSA	ustekinumab	Yes, through the Plan Pharmacy Servces	IMULDOSA (ustekinumab)	IMULDOSA (ustekinumab)	
Medical	J1750	INFED-preferred		As of 08/01/2022: VENOFER, INFED, FERRLECIT, and FERAHEME are the preferred parenteral iron products and do not require prior authorization. INJECTAFER, MONOFERRIC, TRIFERIC, and TRIFERIC AVNU are the non-preferred parenteral iron products and prior authorization is required through the Plan Pharmacy Services.		INFED (iron dextran)	
Medical	Q5103	INFLECTRA - non-preferred	infliximab-dyyb	Yes, through the Plan Pharmacy Services after failed trial of RENFLEXIS. Restricted to a Dermatology, Rheumatology, or Gastroenterology specialist with authorization.	<u>INFLECTRA (infliximab-dyyb)</u>	INFLECTRA (infliximab-dyyb)	MAPD Prior Authorization based on National Coverage Determination (N
Medical	J9198	INFUGEM	premixed gemcitabine in sodium chloride solution	Yes, through the Plan Pharmacy Services	INFUGEM (premixed gemcitabine in sodium chloride solution)	INFUGEM (premixed gemcitabine in sodium chloride solution)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J1439	INJECTAFER - non-preferred	ferric caroxymaltose	As of 08/01/2022: VENOFER, INFED, FERRLECIT, and FERAHEME are the preferred parenteral iron products and do not require prior authorization. INJECTAFER, MONOFERRIC, TRIFERIC, and TRIFERIC AVNU are the non-preferred parenteral iron products and prior authorization is required through the Plan Pharmacy Services with authorization.		INJECTAFER (ferric caroxymaltose)	MAPD Prior Authorization needed outlined in the Medicare Benefit F
Medical	A4359, E2103	Insulin Pumps (MAPD ONLY)		Yes, through Dean Health Plan Utilization Management Department. MAPD ONLY	INSULIN PUMPS	INSULIN PUMPS	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J1566	IVIG, IMMUNE GLOBULIN (GAMMAGARD S/D, CARIMUNE NF)	immune globulin, powder	Yes, through the Plan Pharmacy Services	<u>SCIG (Immune Globulin)</u>	<u>SCIG (Immune Globulin)</u>	MAPD Prior Authorization based on National Coverage Determinatio
Medical	J1599	IVIG, IMMUNE GLOBULIN	immune globulin, liquid	Yes, through the Plan Pharmacy Services	IVIG (Immune Globulin)	IVIG (Immune Globulin)	MAPD Prior Authorization based on National Coverage Determinatio
Medical	Q5109	IXIFI	Infliximab-gbtx	Yes, through the Plan Pharmacy Services after failed trial of AVSOLA. Restricted to a Dermatology, Rheumatology, or Gastroenterology specialist with authorization.	<u>IXIFI (Infliximab-gbtx)</u>	<u>IXIFI (Infliximab-gbtx)</u>	MAPD Prior Authorization based on National Coverage Determinatio
Medical	J2782	IZERVAY	avacincaptad pegol	Yes, through the Plan Pharmacy Services	IZERVAY™ (avacincaptad pegol)	IZERVAY™ (avacincaptad pegol)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J9281	JELMYTO	mitomycin	Yes, through the Plan Pharmacy Services	JELMYTO (mitomycin)	JELMYTO (mitomycin)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J9272	JEMPERLI	dostarlimab	Yes, through the Plan Pharmacy Services	JEMPERLI (dostarlimab-gxly)	JEMPERLI (dostarlimab)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	J9043	JEVTANA	cabazitaxel	Yes, through the Plan Pharmacy Services	JEVTANA (cabazitaxel)	JEVTANA (cabazitaxel)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J3590	JUBBONTI	denosumab	EFFECTIVE 05/01/2025. No prior authorization is required.	JUBBONTI (denosumab)	JUBBONTI (denosumab)	MAPD Prior Authorization based on National Coverage Determinatio
Medical	J9354	KADCYLA	ado-trastuzumab emtansine	Yes, through the Plan Pharmacy Services	KADCYLA (ado-trastuzumab emtansine)	KADCYLA (ado-trastuzumab emtansine)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J1290	KALBITOR	Kalbitor (ecallantide)	Yes, through the Plan Pharmacy Services	KALBITOR (ecallantide)	KALBITOR (ecallantide)	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	Q5117	KANJINTI	trastuzumab-anns	Yes, through the Plan Pharmacy Services	KANJINTI (trastuzumab-anns)	<u>KANJINTI (trastuzumab-anns)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	J2840	KANUMA IV	sebelipase alfa	Yes, through the Plan Pharmacy Services	KANUMA IV (sebelipase alfa)	KANUMA IV (sebelipase alfa)	MAPD Prior Authorization needed outlined in the Medicare Benefit F

	•	
orization or Restrictions	Policy	Prior Authorization Form
f drug you want to locate. If you do not know the few letters of the	e binocular icon on your toolbar. It will then display a search box correct spelling, you can start your search by entering just the first name	

MAPD

	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO.
<u>tacimab-hncq)</u>	
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
izumab-asmn)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
amab-dlle)_	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
mab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mumab-actl)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ene laherparepvec)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>kinumab)</u>	
an)	
imab-dyyb)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
xed gemcitabine in sodium chloride solution)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ic caroxymaltose)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>obulin)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
<u>obulin)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
<u>gbtx)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
ncaptad pegol)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>ycin)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>limab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
axel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
sumab)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
astuzumab emtansine)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ntide)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>umab-anns)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
elipase alfa)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs


ıs	WI,	IL,	МО	•	
	1		1		
15	WI,	IL,	MO		
ıs	WI,	IL,	MO		
ıs	WI,	IL,	МО		
)،	WI,		MO		
	ΨVΙ,	، <i>∟</i> ,	0		

	(formerly WellFirst Health)	IN	IJECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or n coverage review of any drug liste	ing of the most commonly prescribed drugs under the medical benefit ot yet reviewed and whether a prior authorization is required. For ed as not covered, please complete the Exception to Coverage form website for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.		e correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J3590	KEBILIDI	eladocagene exuparvovec-tneq	Yes, through the Plan Pharmacy Services	KEBILIDI (eladocagene exuparvovec-tneg)	KEBILIDI (eladocagene exuparvovec-tneq)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J3490	KETAMINE for Chronic Pain and Mental Health and Substance Related Disorders		None. Not Covered	KETAMINE FOR CHRONIC PAIN		MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J9271	KEYTRUDA	pembrolizumab	Yes, through the Plan Pharmacy Services	KEYTRUDA (pembrolizumab)	KEYTRUDA (pembrolizumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J0642	KHAPZORY	levoleucvorin	Yes, through the Plan Pharmacy Services	KHAPZORY (levoleucvorin)	KHAPZORY (levoleucvorin)	
Medical	J9274	KIMMTRAK	tebentafusp-tebn	Yes, through the Plan Pharmacy Services	KIMMTRAK (tebentafusp-tebn)	KIMMTRAK (tebentafusp-tebn)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J0175	KISUNLA	donanemab-azbt	Yes, through the Plan Pharmacy Services	<u>Kisunla (donanemab-azbt)</u>	<u>Kisunla (donanemab-azbt)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J2507	KRYSTEXXA	pegloticase	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Rheumatologist or Nephrologist specialist with authorization.	KYRSTEXXA (pegloticase)	KRYSTEXXA (pegloticase)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	Q2042	KYMRIAH	tisagenlecleucel	Yes, through the Plan Pharmacy Services	KYMRIAH (tisagenlecleucel)	KYMRIAH (tisagenlecleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J9047	KYPROLIS	carfilzomib	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Oncologist specialist with authorization.	KYPROLIS (carfilzomib)	KYPROLIS (carfilzomib)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J0217	LAMZEDE	velmanase alfa-tycv	Yes, through the Plan Pharmacy Services	LAMZEDE [®] (velmanase alfa-tycv)	LAMZEDE [®] (velmanase alfa-tycv)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J3490, C9399	LANREOTIDE	somatuline depot	Yes, through the Plan Pharmacy Services	LANREOTIDE (somatuline depot)	LANREOTIDE (somatuline depot)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J3590	LANTIDRA	donislecel-jujn	Yes, through the Plan Pharmacy Services	<u>LANTIDRA™ (donislecel-jujn)</u>	<u>LANTIDRA™ (donislecel-jujn)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J0202	LEMTRADA	alemtuzumab	Yes, through the Plan Pharmacy Services. Restricted to Neurology specialist with authorization. Infusions must be administered at a facility certified for LEMTRADA infusions.	<u>LEMTRADA (alemtuzumab)</u>	<u>LEMTRADA (alemtuzumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J3590	LENMELDY	atidarsagene autotemcel	Yes, through the Plan Pharmacy Services	LENMELDY (atidarsagene autotemcel)	LENMELDY (atidarsagene autotemcel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J0174	LEQEMBI	lecanemab-irmb	Yes, through the Plan Pharmacy Services	LEQEMBI™ (lecanemab-irmb)	LEQEMBI™ (lecanemab-irmb)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J1306	LEQVIO	inclisiran	None. Not covered.	LEQVIO (inclisiran)		
Medical	J0650	N/A	Levothyroxine Injection (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Medical physician specialist with authorization.	LEVOTHYROXINE INJECTION (INTRAVENOUS)	LEVOTHYROXINE INJECTION (INTRAVENOUS)	
Medical	J9119	LIBTAYO	cemiplimab	Yes, through the Plan Pharmacy Services	LIBTAYO (cemiplimab-rwlc)	LIBTAYO (cemiplimab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J2001		LIDOCAINE for Chronic Pain	None. Not Covered	LIDOCAINE FOR CHRONIC PAIN		
Medical	J3263	LOQTORZI	toripalimab-tpzi	Yes, through the Plan Pharmacy Services	LOQTORZI (toripalimab-tpzi)	LOQTORZI (toripalimab-tpzi)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J2778	LUCENTIS	ranibizumab	Yes, through the Plan Pharmacy Services	LUCENTIS (ranibizumab)	LUCENTIS (ranibizumab)	MAPD Prior Authorization based on National Coverage Determination (NCD), Lo
Medical	J0221	LUMIZYME	alglucosidase alfa (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Pompe DX with authorization.	LUMIZYME (alglucosidase alfa)	LUMIZYME (alglucosidase alfa) (Intravenous)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J9313	LUMOXITI	moxetumomab pasudotox	Yes, through the Plan Pharmacy Services	LUMOXITI (moxetumomab pasudotox-tdfk)	LUMOXITI (moxetumomab pasudotox)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J9350	LUNSUMIO	mosunetuzumab-axgb	Yes, through the Plan Pharmacy Services	LUNSUMIO (mosunetuzumab-axgb)	LUNSUMIO (mosunetuzumab-axgb)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	A9513	LUTATHERA	lutetium Lu 177 dotatate	Yes, through the Plan Pharmacy Services	LUTATHERA (lutetium Lu 177)	LUTATHERA (lutetium Lu 177 dotatate)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	13398	LUXTURNA	voretigene neparvovec-rzyl	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a specialist who treats the retinal dystrophy with authorization.	LUXTURNA (voretigene neparvovec-rzyl)	LUXTURNA (voretigene neparvovec-rzyl)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J3394	LYFGENIA	lovotibeglogene autoemcel	Yes, through the Plan Pharmacy Services	LYFGENIA (lovotibeglogene autoemcel)	LYFGENIA (lovotibeglogene autoemcel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J9161	LYMPHIR	denileukin diftitox-cxdl)	Yes, through the Plan Pharmacy Services	LYMPHIR (denileukin diftitox-cxdl)	LYMPHIR (denileukin diftitox-cxdl)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J9353	MARGENZA	margetuximab	Yes, through the Plan Pharmacy Services	MARGENZA (margetuximab)	MARGENZA (margetuximab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy I
Medical	J3397	MEPSEVII	vestronidase alfa-vjbk (intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Mucopolysaccharidosis VII with authorization.	MEPSEVII (vestronidase alfa-vjbk) (intravenous)	<u>MEPSEVII (vestronidase alfa-vjbk) (intravenous)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N
Medical	J9349	ΜΟΝJUVI	tafasitamab-cxix	Yes, through the Plan Pharmacy Services	MONJUVI (tafasitamab-cxix)	MONJUVI (tafasitamab-cxix)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy N

Prior Authorization Form	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
brolizumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>eucvorin)</u>	
entafusp-tebn)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nab-azbt)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
l <mark>oticase)</mark>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nlecleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>omib)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
anase alfa-tycv)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
matuline depot)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
iislecel-jujn)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>ituzumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
arsagene autotemcel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>nemab-irmb)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
INJECTION (INTRAVENOUS)	
imab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
alimab-tpzi)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
zumab)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
icosidase alfa) (Intravenous)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
etumomab pasudotox)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
unetuzumab-axgb)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
etium Lu 177 dotatate)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
tigene neparvovec-rzyl)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>beglogene autoemcel)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>ukin diftitox-cxdl)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
getuximab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nidase alfa-vjbk) (intravenous)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
tamab-cxix)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

		1		1	1	7	
	Medica . (formerly WellFirst Health)	IN	IJECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or n coverage review of any drug list	ting of the most commonly prescribed drugs under the medical benefit not yet reviewed and whether a prior authorization is required. For ted as not covered, please complete the Exception to Coverage form website for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the few letters of the	e correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J1437	MONOFERRIC - non-preferred	ferric derisomaltose	As of 08/01/2022: VENOFER, INFED, FERRLECIT, and FERAHEME are the preferred parenteral iron products and do not require prior authorization. INJECTAFER, MONOFERRIC, TRIFERIC, and TRIFERIC AVNU are the non-preferred parenteral iron products and prior authorization is required through the Plan Pharmacy Services with authorization.		MONOFERRIC (ferric derisomaltose)	MAPD Prior Author
Medical	J7327	MONOVISC - non-preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>MONOVISC (hyaluronan or derivative)</u>	MAPD Prior Authoriz
Medical	Q5107	MVASI	bevacizumab-awwb	As of 03/01/2024: Zirabev is the preferred Bevacizumab product and does not require prior authorization. Avastin, Alymsys, Mvasi and Vegzelma prior authorization is required through the Plan Pharmacy Services. ***Prior authorization for bevacizumab is not required when used for ophtalmological indications.*** See the ALYMSYS (bevacizumab) Policy for a list of applicable ophthalmological diagnoses.	MVASI (bevacizumab-awwb)	<u>MVASI (bevacizumab-awwb)</u>	MAPD Prior Author
Medical	J9203	MYLOTARG	gemtuzumab ozogamicin	Yes, through the Plan Pharmacy Services	MYLOTARG (gemtuzumab ozogamicin)	MYLOTARG (gemtuzumab ozogamicin)	MAPD Prior Author
Medical	J0587	MYOBLOC	rimabotulinumtoxinB	No prior authorization is required.	MYOBLOC (rimabotulinumtoxinB)		MAPD Prior Authoriz
Medical	J3490	N/A	Levothyroxine Injection (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Medical physician specialist with authorization.	LEVOTHYROXINE INTRAVENOUS	LEVOTHYROXINE INTRAVENOUS	
Medical	J1458	NAGLAZYME	galsulfase (intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Mucopolysaccharidosis VI with authorization.	NAGLAYME (galsulfase)	NAGLAYME (galsulfase)	MAPD Prior Author
Pharmacy	J2506	NEULASTA	pegfilgrastim	Yes, Through Navitus	NEULASTA (pegfilgrastim)	NEULASTA (pegfilgrastim)	
Medical	J2506	NEULASTA	pegfilgrastim	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	NEULASTA (pegfilgrastim)	NEULASTA (pegfilgrastim)	MAPD Prior Authoriz
Medical	J1442	NEUPOGEN	filgrastim	EFFECTIVE 01/01/2023: Nivestym and Zarxio are the preferred Filgrastim products and do not require prior authorization. Neupogen, Releuko and Granix, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.	NEUPOGEN (filgrastim)	<u>NEUPOGEN (filgrastim)</u>	MAPD Prior Author
Medical	N/A	NEW TO MARKET MEDICAL PHARMACY PRODUCTS CURRENTLY UNDER CLINICAL REVIEW	New to Market Medical Pharmacy Products currently under clinical review	New policy regarding Medical Pharmacy products under current clinical review	NEW TO MARKET MEDICAL PHARMACY PRODUCTS CURRENTLY UNDER CLINICAL REVIEW		
Medical	N/A	NEW TO MARKET MEDICAL PHARMACY PRODUCTS	New to Market Medical Pharmacy Products	New policy regarding New to Market Medical Products	NEW TO MARKET MEDICAL PHARMACY PRODUCTS		
Medical	J0219	NEXVIAZYME	avalglucosiidase alfa	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Pompe DX.	NEXVIAZYME (avalglucosidase alfa)	NEXVIAZYME (avalglucosidase alfa)	MAPD Prior Author
Medical	J9038	ΝΙΚΤΙΜVΟ	axatilimab-csfr	Yes, through the Plan Pharmacy Services	<u>NIKTIMVO (axatilimab-csfr)</u>	NIKTIMVO (axatilimab-csfr)	MAPD Prior Author
Medical	Q5110	NIVESTYM	filgrastim-aafi	EFFECTIVE 01/01/2023: Nivestym and Zarxio are the preferred Filgrastim products and do not require prior authorization. Neupogen, Releuko and Granix, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.	<u>NIVESTYM (filgrastim-aafi)</u>	NIVESTYM (filgrastim-aafi)	MAPD Prior Author
Medical	J2802	NPLATE	romipostim	Yes, through the Plan Pharmacy Services	NPLATE (romipostim)	NPLATE (romipostim)	MAPD Prior Author
Medical	J2182	NUCALA	mepolizumab	Yes, through the Plan Pharmacy Services. Eosinophilic asthma: Restricted to Pulmonology, Allergy, and Immunology specialists with authorization. Eosinophilic granulomatosis with polyangitis (EGPA): Restricted to a Pulmonology, Immunology, Allergy or Rheumatology specialist with authorization.	NUCALA (mepolizumab)	NUCALA (mepolizumab)	MAPD Prior Authoriz
Medical	J3490, C9399	NULIBRY	fosdenopterin	Yes, through the Plan Pharmacy Services. Restricted to a neurologist, medical geneticist, or a provider who specializes in management of inborn errors of metabolism with authorization.	NULIBRY (fosdenopterin)	NULIBRY (fosdenopterin)	MAPD Prior Author
Medical	Q5148	ΝΥΡΟΖΙ	filgrastim-txid	EFFECTIVE 01/01/2023: Nivestym and Zarxio are the preferred Filgrastim products and do not require prior authorization. Neupogen, Releuko and Granix, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.	<u>NYPOZI (filgrastim-txid)</u>	NYPOZI (filgrastim-txid)	MAPD Prior Author
Medical	Q5122	NYVEPRIA	pegfligrastim-apgf	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	<u>NYVEPRIA (pegfligrastim-apgf)</u>	NYVEPRIA (pegfligrastim-apgf)	MAPD Prior Author
Medical	J2350	OCREVUS	ocrelizumab	Yes, through the Plan Pharmacy Services. Restricted to Neurology specialists with authorization.	OCREVUS (ocrelizumab)	OCREVUS (ocrelizumab)	MAPD Prior Author
Medical	J2351	OCREVUS ZUNOVO	ocrelizumab and hyaluronidase-ocsq)	Yes, through the Plan Pharmacy Services	OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq)	OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq)	MAPD Prior Author

MAPD
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO.
Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO.
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs



	(formerly WellFirst Health)	INJ	ECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or not coverage review of any drug listed	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For a as not covered, please complete the Exception to Coverage form rebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the few letters of the	e correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J1568	OCTAGAM (IVIG), IMMUNE GLOBULIN	immune globulin (octagam liquid)	Yes, through the Plan Pharmacy Services	OCTAGAM (IVIG)	OCTAGAM (IVIG)	MAPD Prior Authorization based on National Coverage Determination (NC
Medical	Q5114	OGIVRI	trastuzumab-dkst	Herzuma and Trazimera are the preferred Trastuzumab products and do not require prior authorization. Herceptin, Ogivri, Kanjinti and Ontruzant, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.		<u>OGIVRI (trastuzumab-dkst)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J3590	OMSIGRE	omidubicel-onlv	Yes, through the Plan Pharmacy Services	OMISIRGE [®] (omidubicel-only)	OMISIRGE [®] (omidubicel-only)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J2267	омvон	mirikizumab-mrkz	Yes, through the Plan Pharmacy Services	OMVOH (mirikizumab-mrkz)	<u>ОМVOH (mirikizumab-mrkz)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9205	ONIVYDE	irinotecan liposome injection	Yes, through the Plan Pharmacy Services	ONIVYDE (irinotecan liposome injection)	ONIVYDE (irinotecan liposome injection)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J0222	ONPATTRO	patisiran	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Oncology, Hematology or Neurology specialist with authorization.	<u>ONPATTRO (patisiran)</u>	ONPATTRO (patisiran)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Man
Medical	Q5112	ONTRUZANT	trastuzumab-dttb	Herzuma and Trazimera are the preferred Trastuzumab products and do not require prior authorization. Herceptin, Ogivri, Kanjinti and Ontruzant, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.		ONTRUZANT (trastuzumab-dttb)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9299	OPDIVO	nivolumab	Yes, through the Plan Pharmacy Services	<u>OPDIVO (nivolumab)</u>	<u>OPDIVO (nivolumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9999	OPDIVO QVANTIG	nivolumab and hyaluronidase-nvhy	Yes, through the Plan Pharmacy Services	OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy)	OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy)	
Medical	J9298	OPDUALAG	nivolumab/relatlimab-rmbw	Yes, through the Plan Pharmacy Services	<u>OPDUALAG (nivolumab/relatlimab-rmbw)</u>	OPDUALAG (nivolumab/relatlimab-rmbw)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J3590	OPUVIZ	aflibercept	Yes, through the Plan Pharmacy Services	<u>OPUVIZ (aflibercept)</u>	OPUVIZ (aflibercept)	
Medical	J0129	ORENCIA (IV)	abatacept	Yes, through the Plan Pharmacy Services. Restricted to an Rheumatology specialist with authorization.	ORENCIA IV (abatacept)	ORENCIA IV (abatacept)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Man
Pharmacy	J0129	ORENCIA (SC)	abatacept	Yes, through Navitus. Restricted to an Rheumatology specialist with authorization.	ORENCIA SC (abatacept)	ORENCIA SC (abatacept)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Man
Medical	J7324	ORTHOVISC - non-preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		ORTHOVISC (hyaluronan or derivative)	MAPD Prior Authorization based on National Coverage Determination (NCD), Lo
Medical	Q9999	OTULFI	ustekinumab	Yes, through the Plan Pharmacy Services.	<u>OTULFI (ustekinumab)</u>	<u>OTULFI (ustekinumab)</u>	
Medical	J0224	OXLUMO	lumasiran	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Nephrologist or Urologist specialist with authorization.	<u>OXLUMO (lumasiran)</u>	<u>OXLUMO (lumasiran)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9529	PACLITAXEL PROTEIN-BOUND PARTICLES		Yes, through the Plan Pharmacy Services	PACLITAXEL PROTEIN-BOUND PARTICLES	PACLITAXEL PROTEIN-BOUND PARTICLES	MAPD Prior Authorization based on National Coverage Determination (NCI
Medical	J9177	PADCEV	enfortumab vedotin-ejfv	Yes, through the Plan Pharmacy Services	PADCEV (enfortumab vendotin-ejfv)	PADCEV (enfortumab vedotin-ejfv)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	Q5147	PAVBLU	aflibercept	Yes, through the Plan Pharmacy Services	PAVBLU (aflibercept)	PAVBLU (aflibercept)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J0208	PEDMARK	soodium thiosulfate	Yes, through the Plan Pharmacy Services	PEDMARK [®] (sodium thiosulfate)	PEDMARK [®] (sodium thiosulfate)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9304	PEMFEXY	pemetrexed	Yes, through the Plan Pharmacy Services	PEMFEXY (pemetrexed)	PEMFEXY (pemetrexed)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9324	PEMRYDI	pemetrexed	Yes, through the Plan Pharmacy Services	PEMRYDI (pemetrexed)	PEMRYDI (pemetrexed)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Man
Medical	J9306	PERJETA	pertuzumab	Yes, through the Plan Pharmacy Services	<u>PERJETA (pertuzumab)</u>	PERJETA (pertuzumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9316	PHESGO	pertuzumab, trastuzumab, hyaluronidase	Yes, through the Plan Pharmacy Services	PHESGO (pertuzumab)	PHESGO (pertuzumab, trastuzumab, hyaluronidase)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J1307	PIASKY	crovalimab-akkz	Yes, through the Plan Pharmacy Services	<u>Piasky (crovalimab-akkz)</u>	<u>Piasky (crovalimab-akkz)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	A9699	PLUVICTO	lutetium Lu 177 vipivotide tetraxetan	Yes, through the Plan Pharmacy Services	PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)	<u>PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9309	POLIVY	polatuzumab vedotin-piiq	Yes, through the Plan Pharmacy Services	POLIVY (polatuzumab vedotin-piiq)	POLIVY (polatuzumab vedotin-piiq)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J1203	POMBILITI	cipaglucosidase alfa-atga	Yes, through the Plan Pharmacy Services	POMBILITI (cipaglucosidase alfa-atga)	POMBILITI (cipaglucosidase alfa-atga)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy
Medical	J9295	PORTRAZZA	necitumumab	Yes, through the Plan Pharmacy Services	PORTRAZZA (necitumumab)	PORTRAZZA (necitumumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy

Prior Authorization Form	MAPD
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
<u>nab-dkst)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
lubicel-onlv)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>mab-mrkz)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
can liposome injection)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
i <u>ran)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>tuzumab-dttb)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>ab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
G (nivolumab and hyaluronidase-nvhy)	
umab/relatlimab-rmbw)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>pt)</u>	
acept)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
acept)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>uronan or derivative)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
<u>nab)</u>	
<u>an)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
EIN-BOUND PARTICLES	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
<u>mab vedotin-ejfv)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ept)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ım thiosulfate)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
rexed)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
trexed)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mab, trastuzumab, hyaluronidase)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>b-akkz)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ım Lu 177 vipivotide tetraxetan)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mab vedotin-piiq)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ucosidase alfa-atga)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
:umumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

is WI, IL, MO	
ns WI, IL, MO	
	_

	(formerly WellFirst Health)	INJ	ECTABLE MEDICINES	SEARCH TIPS:			
		This reference guide is a partial listing of the most commonly prescribed drugs under the medical benefit are covered, not covered, or not yet reviewed and whether a prior authorization is required. For coverage review of any drug listed as not covered, please complete the Exception to Coverage form found on the WellFirst Health website for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.		t This is a large document, but you can search quickly and easily by clicking on for you to type in the name of drug you want to locate. If you do not know the few letters of the			
Benefit	Updated: 05/01/2025	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J2468	POSFREA	palonosetron	Yes, through the Plan Pharmacy Services	POSFREA (palonosetron)	POSFREA (palonosetron)	
Medical	J9204	POTELIGEO		Yes, through the Plan Pharmacy Services	POTELIGEO (mogamulizumab-kpkc)	POTELIGEO (mogamulizumab-kpkc)	MAPD Prior A
Medical	J1459	PRIVIGEN (IVIG), IMMUNE GLOBULIN	mogamulizumab-kpkc) privigen	Yes, through the Plan Pharmacy Services	PRIVIGEN (IVIG)	PRIVIGEN (IVIG)	MAPD Prior Au
Pharmacy	J0885	PROCRIT - non-preferred	epoetin alfa, (for non-esrd use)	Yes, through Navitus. Restricted to (in at least consultation with) a Oncology, Infectious Disease, Hematology, or Nephrology specialist with authorization.	PROCRIT (epoetin alpha)	PROCRIT (epoetin alpha)	MAPD Prior A
Medical	J0885, Q4082	PROCRIT	epoetin alfa, (for non-esrd use)	As of 01/01/2023: Retacrit is the preferred Epoetin Alfa products and does not require prior authorization. Epogen and Procrit prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria.	PROCRIT (epoetin alfa, (for non-ersd use)	PROCRIT epoetin alfa, (for non-esrd use)	MAPD Prior A
Medical	J9015	PROLEUKIN	aldesleukin	Yes, through the Plan Pharmacy Services	PROLEUKIN (aldesleukin)	PORLEUKIN (aldesleukin)	MAPD Prior A
Medical	J0897	PROLIA	denosumab	EFFECTIVE 05/01/2025. No prior authorization is required.	PROLIA (denosumab)	<u>PROLIA (denosumab)</u>	MAPD Prior Au
Medical	Q2043	PROVENGE	sipuleucel-T	Yes, through the Plan Pharmacy Services	PROVENGE (sipuleucel-T)	PROVENGE (sipuleucel-T)	MAPD Prior A
Medical	Q9997	PYZCHIVA	ustekinumab-ttwe	Yes, through the Plan Pharmacy Services	PYZCHIVA (ustekinumab-ttwe)	<u>PYZCHIVA (ustekinumab-ttwe)</u>	
Medical	J1304	QALSODY	tofersen	Yes, through the Plan Pharmacy Services	QALSODY™ (tofersen)	QALSODY™ (tofersen)	MAPD Prior A
Medical	J1301	RADICAVA	edaravone	Yes, through the Plan Pharmacy Services. Restricted to an Neurology specialist with authorization.	RADICAVA (edaravone)	RADICAVA (edaravone)	MAPD Prior Au
Medical	J0896	REBLOZYL	lusptercept	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Oncologist specialist with authorization.	<u>REBLOZYL (luspatercept-aamt)</u>	REBLOZYL (luspatercept)	MAPD Prior Au
Medical	Q5125	RELEUKO	filgrastim-ayow	EFFECTIVE 01/01/2023: Nivestym and Zarxio are the preferred Filgrastim products and do not require prior authorization. Neupogen, Releuko and Granix, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.		<u>RELEUKO (filgrastim-ayow)</u>	MAPD Prior A
Medical	J1745	REMICADE - non-preferred	infliximab	Yes, through the Plan Pharmacy Services after failed trial of RENFLEXIS. Restricted to a Dermatology, Rheumatology, or Gastroenterology specialist with authorization.	<u>REMICADE (infliximab)</u>	<u>REMICADE (infliximab)</u>	MAPD Prior Au
Medical	J3285	REMODULIN IV	treprostinil	Generic Treprostinil will be covered with prior Authorization through the Plan Pharmacy Services. Brand REMODULIN will not be covered. Restricted to (in at least consultation with) a Cardiology or Pulmonology specialists with authorization.	REMODULIN IV (treprostinil)	<u>REMODULIN IV (treprostinil)</u>	MAPD Prior A
Medical	Q5104	RENFLEXIS - preferred infliximab product	infliximab-abda	As of 10/01/2019: Prior authorization for the preferred infliximab product will only require provider attestation to an appropriate indication through the Plan Pharmacy Services. Restricted to a Dermatology, Rheumatology, or Gastroenterology specialist with authorization.	PENELEXIS (inflivimab)	<u>RENFLEXIS (infliximab)</u>	MAPD Prior Au
Pharmacy	Q5105	RETACRIT - preferred	epoetin alfa-epbx	Yes, through Navitus. Restricted to (in at least consultation with) a Oncology, Infectious Disease, Hematology, or Nephrology specialist with authorization.	RETACRIT (epoetin alfa-epbx)	<u>RETACRIT (epoetin alfa-epbx)</u>	
Medical	Q5106	RETACRIT	epoetin alfa-epbx	As of 01/01/2023: Retacrit is the preferred Epoetin Alfa products and does not require prior authorization. Epogen and Procrit prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria.	RETACRIT (epoetin alfa-epbx)	RETACRIT (epoetin alfa-epbx)	MAPD Prior A
Medical	J7311	RETISERT	fluocinolone acetonide intravitreal implant	None. Not Covered.	RETISERT (fluocinolone acetonide intravitreal implant)		
Medical	J3590	RETHYMIC	allogeneic processed thymus tissue-agdc)	Yes, through the Plan Pharmacy Services	RETHYMIC (allogenic processed thymus tissue-agdc)	RETHYMIC (Allogenic processed thymus tissue-agdc)	MAPD Prior A
Medical	J3590, C9399	REVCOVI	elapegademase-lvlr	Yes, through the Plan Pharmacy Services	REVCOVI® (elapegademase-lvlr)	REVCOVI [®] (elapegademase-lvlr)	MAPD Prior A
Pharmacy		RHOPRESSA	netarsudil	PHARMACY BENEFIT ONLY. Yes, through Navitus.	RHOPRESSA (netarsudil)	<u>RHOPRESSA (netarsudil)</u>	
Medical	Q5123	RIABNI	rituximab-arrx	As of 01/01/2023: Ruxience and Truxima are the preferred Rituximab products and does not require prior authorization. Riabni and Rituxan prior authorization is required. Please see medical policy for criteria	<u>RIABNI (rituximab-arrx)</u>	<u>RIABNI (rituximab)</u>	MAPD Prior A
Medical	J3490	RIVFLOZA	nedosiran	Yes, through the Plan Pharmacy Services	RIVFLOZA (nedosiran)	<u>RIVFLOZA (nedosiran)</u>	MAPD Prior A
Medical	J9312	RITUXAN	rituximab	As of 01/01/2023: Ruxience and Truxima are the preferred Rituximab products and does not require prior authorization. Riabni and Rituxan prior authorization is required. Please see medical policy for criteria	<u>RITUXAN (rituximab)</u>	<u>RITUXAN (rituximab)</u>	MAPD Prior A
Medical	J9311	RITUXAN HYCELA	rituximab and hyaluronidase human	Yes, through the Plan Pharmacy Services	RITUXAN HYCELA (rituximab and hyaluronidase human)	RITUXAN HYCELA (rituximab and hyaluronidase human)	MAPD Prior A
Medical	J9312	RITUXIMAB IV	rituxan, truxima, ruxiencem riabni	Yes, through the Plan Pharmacy Services	RITUXIMAB IV (rituxan, truxima, ruxience, riabni)	<u>RITUXIMAB IV (rituxan, truxima, ruxiencem riabni)</u>	MAPD Prior A
Medical	J1412	ROCTAVIAN	valoctocogene roxaparvovec-rvox	Yes, through the Plan Pharmacy Services	ROCTAVIAN [®] (valoctocogene roxaparvovec-rvox)	ROCTAVIAN [®] (valoctocogene roxaparvovec-rvox)	MAPD Prior A

MAPD rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO. rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO ior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions ior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO. or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs r Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO. rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions ior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals or Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction rior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO rior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO or Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO ior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

-		-		
				_
				_
S	WI,	IL,	MO.	
	\\\/I		MO	
5	VV1,	ιι,	MO.	
S	WI,	IL,	МО	
S	WI,	IL,	МО	
S	WI,	IL,	МО	

		1		I		7	
	Medica. INJECTABLE MEDICINES (formerly WellFirst Health) 1		SEARCH TIPS:		_		
		are covered, not covered, or not coverage review of any drug listed	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For d as not covered, please complete the Exception to Coverage form rebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	This is a large document, but you can search quickly and easily by clicking on the binocular icon on your toolbar. It will then display a search box for you to type in the name of drug you want to locate. If you do not know the correct spelling, you can start your search by entering just the first few letters of the name			
Benefit	Updated: 05/01/2025	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
	J1449 Q5119	ROLVEDON	rituximab-pvvr	Yes, through the Plan Pharmacy Services As of 01/01/2023: Ruxience and Truxima are the preferred Rituximab products and does not require prior authorization. Riabni and Rituxan prior authorization is required. Please see medical policy for criteria	ROLVEDON™ (eflapegrastim-xnst) RUXIENCE (rituximab-pvvr)	ROLVEDON™ (eflapegrastim-xnst) RUXIENCE (rituximab-pvvr)	MAPD Prior Authorization needed outlined in the MAPD Prior Authorization based on National Cov
Medical	J9061	RYBREVANT		Yes, through the Plan Pharmacy Services	<u>RYBREVANT (amivantamb-vmjw)</u>	<u>RYBREVANT (amivantamab-vmjw)</u>	MAPD Prior Authorization needed outlined in the
Medical	J3590	RYONCIL	remestemcel-L-rknd	Yes, through the Plan Pharmacy Services	RYONCIL (remestemcel-L-rknd)	RYONCIL (remestemcel-L-rknd)	MAPD Prior Authorization based on National Cov
Medical	J2998	RYPLAZIM	plasminogen, human-tvmh	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a medical Hematologist or MD specializing in plasminogen deficiency (PLGD) with authorization.	RYPLAZIM (plasminogen, human-tvmh)	RYPLAZIM (plasminogen, human tvmh)	MAPD Prior Authorization needed outlined in the
Medical	J9333	RYSTIGGO	rozanolixizumab-noli	Yes, through the Plan Pharmacy Services	<u>RYSTIGGO[®] (rozanolixizumab-noli)</u>	RYSTIGGO [®] (rozanolixizumab-noli)	MAPD Prior Authorization needed outlined in the
Medical	J0870	RYTELO	imetelstat	EFFECTIVE 10/01/2024. Yes, through the Plan Pharmacy Services	<u>Rytelo (imetelstat)</u>	<u>Rytelo (imetelstat)</u>	MAPD Prior Authorization based on National Cov
Medical	J9361	RYZNEUTA	efbemalenograstim alfa-vuxw	Yes, through the Plan Pharmacy Services	<u>RYZNEUTA (efbemalenograstim alfa-vuxw)</u>	<u>RYZNEUTA (efbemalenograstim alfa-vuxw)</u>	MAPD Prior Authorization needed outlined in the
Pharmacy		SANDOSTATIN	octreotide	Yes, through Navitus. Restricted to (in at least consultation with) a Endocrinologist, Oncologist, or Gastroenterologist specialist with authorization.	SANDOSTATIN (octreotide acetate)		
Medical	J2353	SANDOSTATIN LAR	octreotide suspension	Yes, through the Plan Pharmacy Services	SANDOSTATIN LAR (octreotide suspension)	SANDOSTATIN LAR (octreotide suspension)	MAPD Prior Authorization needed outlined in the
Medical	J2354	SANDOSTATIN	octreotide suspension (non-depot form)	Yes, through the Plan Pharmacy Services	SANDOSTATIN octreotide suspension (non-depot form)	SANDOSTATIN octreotide suspension (non-depot form)	MAPD Prior Authorization needed outlined in the
Medical	J0491	SAPHNELO	lanifroiliman-fnia	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Rheumatology specialist with authorization.	<u>SAPHNELO (anifrolumab-fnia)</u>	<u>SAPHNELO (anifrolumab-fnia)</u>	MAPD Prior Authorization needed outlined in the M
Medical	J9227	SARCLISA	isatuximab-irfc	Yes, through the Plan Pharmacy Services	SARCLISA (isatuximab-irfc)	SARCLISA (isatuximab-irfc)	MAPD Prior Authorization needed outlined in the
Medical	J7352	SCENESSE	afamelanotide	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Dermatologist, Medical Geneticist, or a Physician specializing in the treatment of cutaneous porphyrias with authorization.	SCENESSE (afamelanotide)	<u>SCENESSE (afamelanotide)</u>	MAPD Prior Authorization needed outlined in the
Medical	Q9998	SELARSDI	ustekinumab-aekn	Yes, through the Plan Pharmacy Services	<u>SELARSDI (ustekinumab-aekn)</u>	<u>SELARSDI (ustekinumab-aekn)</u>	
Pharmacy		SELF-ADMINISTERED DRUGS		PHARMACY BENEFIT ONLY. Verify prior authorization requirements by accessing the members formulary.	SELF-ADMINISTERED DRUGS		
Medical	J2502	SIGNIFOR LAR	Inacirentide	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Endocrinologist specialist with authorization.	<u>SIGNIFOR LAR (pasireortide)</u>	<u>SIGNIFOR LAR (pasireortide)</u>	MAPD Prior Authorization needed outlined in the
Medical	J1602	SIMPONI ARIA	golimumab	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Rheumatology (Rheumatoid Arthritis, Peripheral Ankylosing Spondylitis, or Psoriatic Arthritis) or Gastroenterology specialist with authorization.	SIMPONI ARIA (golimumab)	SIMPONI ARIA (golimumab)	MAPD Prior Authorization needed outlined in the M
Pharmacy		SIMPONI ARIA	golimumab	Yes, through Navitus. Restricted to (in at least consultation with) an Rheumatology (Rheumatoid Arthritis, Peripheral Ankylosing Spondylitis, or Psoriatic Arthritis) or Gastroenterology specialist with authorization.	<u>SIMPONI ARIA (golimumab)</u>	SIMPONI ARIA (golimumab)	MAPD Prior Authorization needed outlined in the M
Medical		SITE OF SERVICE		Yes, through the Plan Pharmacy Services. Requests for select specialty drugs as listed in the list in section 'Drugs in Scope' to be administered in a hospital outpatient setting may be directed to a preferred alternative site of care, such as home infusion provider or a physician office.	<u>SITE OF SERVICE</u>		
Medical	J2327	SKYRIZI IV	risankizumab	Yes, through Plan Pharmacy Services. Restricted to Gastroenterolgy.	<u>SKYRIZI IV (risankizumab)</u>	SKYRIZZI IV (risankizumab)	MAPD Prior Authorization needed outlined in the
Medical	J3590	SKYSONA	elivaldogene autotemcel	Yes, through the Plan Pharmacy Services	SKYSONA [®] (elivaldogene autotemcel)	SKYSONA [®] (elivaldogene autotemcel)	MAPD Prior Authorization needed outlined in the
Medical	J1300	SOLIRIS	eculizumab	Yes, through the Plan Pharmacy Services. Restricted to a Neurologist or Nuero-Opthalmonogist, Nephrology, Hematology, Oncology, or Transplant specialist with authorization.	<u>SOLIRIS (eculizumab)</u>	<u>SOLIRIS (eculizumab)</u>	MAPD Prior Authorization based on National Covera
Medical	J1930	SOMATULINE	lanreotide depot	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Endocrinologist, Oncologist, or gastroenterologist specialist with authorization.	SOMATULINE (lanreotide depot)	SOMATULINE (lanreotide depot)	MAPD Prior Authorization needed outlined in the M

orm	MAPD
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>ot form)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

าร	WI,	IL,	MO	•			
าร	WI,	IL,	мо				
		_		_	_		
	14/1		N40				
15	vv1,	ις,	MO				
				_	_	_	
_							
_							
_							

		Medica . merly WellFirst Health)	INJ	ECTABLE MEDICINES	SEARCH TIPS:			
			are covered, not covered, or not coverage review of any drug listed found on the WellFirst Health we	g of the most commonly prescribed drugs under the medical benefic yet reviewed and whether a prior authorization is required. For l as not covered, please complete the Exception to Coverage form ebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.		e correct spelling, you can start your search by entering just the first		
Benefit		Updated: 05/01/2025	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J1747		SPEVIGO	spesolimab	Yes, through the Plan Pharmacy Services	<u>SPEVIGO® (spesolimab)</u>	<u>SPEVIGO® (spesolimab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit F
Medical	S0013		SPRAVATO	esketamine	Yes, through the Plan Pharmacy Services	SPRAVATO (esketamine)	SPRAVATO (esketamine)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	J2326		SPINRAZA	nusinersen	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Neurology specialist with expertise in SMA treatment with authorization.	<u>SPINRAZA (nusinersen)</u>	<u>SPINRAZA (nusinersen)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit R
Medical	J3358		STELARA (IV)	ustekinumab	Yes, through the Plan Pharmacy Services. Restricted to an Gastroenterology specialist with authorization.	STELARA IV (ustekinumab)	STELARA IV (ustekinumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Polic
Pharmacy	J3358		STELARA (SC)	ustekinumab	Yes, through Navitus. Restricted to an Gastroenterology specialist with authorization.	STELARA SC (ustekinumab)	STELARA SC (ustekinumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Polic
Medical	J3590		STEQEYMA	ustekinumab	Yes, through the Plan Pharmacy Serivces.	STEQEYMA (ustekinumab)	STEQEYMA (ustekinumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit R
Medical	J3590		STIMUFEND	pegfilgrastim-pbbk	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	<u>STIMUFEND (pegfilgrastim-pbbk)</u>	<u>STIMUFEND (pegfilgrastim-pbbk)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit F
Pharmacy			for ALLERGY products	GRASTEK (Timothy grass pollen allergen extract), RAGWITEK (Short ragweed pollen allergen extract), ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens allergen extract), ODACTRA (House Dust Mite allergen extractt)	Yes, through Navitus. Must be prescribed by an allergist, immunologist, or physician with active and ongoing experience in the diagnosis and treatment of allergic disease and use of immunotherapy products with authorization	SLIT for Allergy Products	SLIT for Allergy Products	
Medical	J7321		SUPARTZ FX - non-preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>SUPARTZ FX (hyaluronan or derivative)</u>	MAPD Prior Authorization based on National Coverage Determinatio
Medical	J1627		SUSTOL	granisetron extended-release	Yes, through the Plan Pharmacy Services	SUSTOL (granisetron extended-release)	SUSTOL (granisetron extended-release)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	J2781		SYFOVRE	pegcetacoplan	No. Please see medical policy for criteria.	SYFOVRE (pegcetacoplan)		MAPD Prior Authorization needed outlined in the Medicare Benefit R
Medical	J2779		SUSVIMO	ranibizumab	Yes, through the Plan Pharmacy Services.	SUSVIMO (ranibisumab)	<u>SUSVIMO (ranibisumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	J2860		SYLVANT	siltuximab	Yes, through the Plan Pharmacy Services	<u>SYLVANT (siltuximab)</u>	<u>SYLVANT (siltuximab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit R
Medical	90378		SYNAGIS	palivizumab	Yes, through the Plan Pharmacy Services. Restricted to NICU Physician, Neonatologist, or Pediatric specialist (including family practice, general pediatrics, pediatric pulmonology, and pediatric cardiology) with authorization.	<u>SYNAGIS (palivizumab)</u>	<u>SYNAGIS (palivizumab)</u>	MAPD Prior Authorization based on National Coverage Determinatio
Medical	J7325		SYNVISC - preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria			MAPD Prior Authorization based on National Coverage Determination (N
Medical	J7325		SYNVISC ONE - preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria			MAPD Prior Authorization based on National Coverage Determination (N
Medical	J3055		TALVEY	talquetamab-tgvs	Yes, through the Plan Pharmacy Serices	<u>TALVEY™ (talquetamab-tgvs)</u>	<u>TALVEY™ (talquetamab-tgvs)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit I
Medical	Q2053		TECARTUS	brexucabtagene autoleucel	Yes, through the Plan Pharmacy Services	TECARTUS (atezolizumab)	TECARTUS (brexucabtagene autoleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	Q2057		TECELRA	afamitresgene autoleucel)	Yes, through the Plan Pharmacy Services	TECELRA (afamitresgene autoleucel)	TECELRA (afamitresgene autoleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit F
Medical	J9022		TECENTRIQ	atezolizumab	Yes, through the Plan Pharmacy Services	TECENTRIQ (atezolizumab)	TECENTRIQ (atezolizumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	J9024		TECENTRIQ HYBREZA	atezolizumab and hyaluronidase-tqjs)	Yes, through the Plan Pharmacy Services	TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tojs)	TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs)	MAPD Prior Authorization needed outlined in the Medicare Benefit
Medical	C9148		TECVAYLI	teclistamab-cqyv	Yes, through the Plan Pharmacy Services	<u>TECVAYLI (teclistamab-cqyv)</u>	TECVAYLI (teclistamab-cqyv)	MAPD Prior Authorization needed outlined in the Medicare Benefit F
				•			•	- .

Prior Authorization Form	MAPD
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
etamine)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>nersen)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>tekinumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
gfilgrastim-pbbk)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
Products	
<u>aluronan or derivative)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
tron extended-release)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
isumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>mab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>umab)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO.
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
<u>etamab-tgvs)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ucabtagene autoleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
tresgene autoleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>zolizumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
REZA (atezolizumab and hyaluronidase-tqjs)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
tamab-cqyv)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

	Medica	IN	IJECTABLE MEDICINES				
	(formerly WellFirst Health)	This reference guide is a partial list are covered, not covered, or no	ing of the most commonly prescribed drugs under the medical benefit ot yet reviewed and whether a prior authorization is required. For ed as not covered, please complete the Exception to Coverage form	SEARCH TIPS: t This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the			
	Updated: 05/01/2025		website for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	few letters of the			
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J3241	TEPEZZA	teprotumumab-trbw	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Ophthalmologist and Endocrinologist specialist with authorization.	TEPEZZA (teprotumumab-trbw)	<u>TEPEZZA (teprotumumab-trbw)</u>	MAPD Prior Authorization needed outlined in t
Medical	J9999, C9399	TEVIMBRA	tislelizumab-jsgr	Yes, through the Plan Pharmacy Services	<u>TEVIMBRA (tislelizumab-jsgr)</u>	TEVIMBRA (tislelizumab-jsgr)	MAPD Prior Authorization needed outlined in t
Medical	J2356	TEZSPIRE	tezepelumab	Yes, through the Plan Pharmacy Services	TEZSPIRE (tezepelumab)	TEZSPIRE (tezepelumab)	MAPD Prior Authorization needed outlined in t
Medical	J9273	TIVDAK	tisotumab vedotin-tftv)	Yes, through the Plan Pharmacy Services	<u>TIVDAK (tisotumab vedotin-tftv)</u>	<u>TIVDAK (tisotumab vedotin-tftv))</u>	MAPD Prior Authorization needed outlined in t
Medical	Q5133	TOFIDENCE	tocilizumab-bavi	Yes, through the Plan Pharmacy Services	TOFIDENCE (tocilizumab-bavi)	TOFIDENCE (tocilizumab-bavi)	MAPD Prior Authorization needed outlined in t
Medical	Q5116	TRAZIMERA	trastuzumab-qyyp	Herzuma and Trazimera are the preferred Trastuzumab products and do not require prior authorization. Herceptin, Ogivri, Kanjinti and Ontruzant, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.		TRAZIMERA (trastuzumab-qyyp)	MAPD Prior Authorization needed outlined in t
Medical	J9033	TREANDA	bendamustine	Yes, through the Plan Pharmacy Services	TREANDA (bendamustine)	TREANDA (bendamustine)	MAPD Prior Authorization needed outlined in t
Medical	J1628	TREMFYA	guselkumab	Yes, through the Plan Pharmacy Services	TREMFYA (guselkumab)	TREMFYA (guselkumab)	MAPD Prior Authorization needed outlined in t
Medical	J7332	TRILURON - preferred	sodium hyaluronate	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred products. No Prior Authorization needed for preferred product	TRILURON (sodium hyaluronate)		MAPD Prior Authorization based on National Co
Medical	J7329	TRIVISC - non-preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>TRIVISC (hyaluronan or derivative)</u>	MAPD Prior Authorization based on National Cove
Medical	J9317	TRODELVY	sacituzumab govitecan-hziy	Yes, through the Plan Pharmacy Services	TRODELVY (sacituzumab govitecan-hziy)	TRODELVY (sacituzumab govitecan-hziy)	MAPD Prior Authorization needed outlined in t
Medical	J1746	TROGARZO	ibalizumab	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an Infectious Disease specialist with authorization.	TROGARZO (ibalizumab)	TROGARZO (ibalizumab)	MAPD Prior Authorization needed outlined in t
Medical	Q5115	TRUXIMA	rituximab-abbs	As of 01/01/2023: Ruxience and Truxima are the preferred Rituximab products and does not require prior authorization. Riabni and Rituxan prior authorization is required. Please see medical policy for criteria	TRUXIMA (rituximab-abbs)	<u>TRUXIMA (rituximab-abbs)</u>	MAPD Prior Authorization based on National Co
Medical	J3590	TYENNE	tocilizumab	Yes, through the Plan Pharmacy Services	<u>TYENNE (tocilizumab)</u>	TYENNE (tocilizumab)	MAPD Prior Authorization needed outlined in t
Medical	Q5134	ΤΥRUKO	natalizumab	Yes, though the Plan Pharmacy Services	<u>TYRUKO (natalizumab)</u>	<u>TYRUKO (natalizumab)</u>	MAPD Prior Authorization needed outlined in t
Medical	J2323	TYSABRI	natalizumab injection	Yes, through the Plan Pharmacy Services. Restricted to a Neurology or Gastroenterology specialist with authorization.	<u>TYSABRI (natalizumab)</u>	<u>TYSABRI (natalizumab)</u>	MAPD Prior Authorization needed outlined in the
Medical	C9149	TZIELD	teplizumab-mzwv	Yes, through the Plan Pharmacy Services	<u>TZIELD (teplizumab-mzwv)</u>	<u>TZIELD (teplizumab-mzwv)</u>	MAPD Prior Authorization needed outlined in t
Medical	Q5111	UDENYCA	pegfligrastim-cbqv	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	<u>UDENCYA (pegfligrastim-cbqv)</u>	<u>UDENCYA (pegfligrastim-cbqv)</u>	MAPD Prior Authorization needed outlined in t
Medical	J1303	ULTOMIRIS	ravulizumab	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Hematology, Oncology, or Immunology specialist with authorization.	ULTOMIRIS (ravulizumab)	<u>ULTOMIRIS (ravulizumab)</u>	MAPD Prior Authorization needed outlined in t
Medical	19999	UNLOXCYT	cosibelimab-ipdl	Yes, through the Plan Pharmacy Services	UNLOXCYT (cosibelimab-ipdl)	UNLOXCYT (cosibelimab-ipdl)	
Medical	J1823	UPLIZNA	inebilizumab-cdon	Yes, through the Plan Pharmacy Services	<u>UPLIZNA (inebilizumab-cdon)</u>	UPLIZNA (inebilizumab-cdon)	MAPD Prior Authorization needed outlined in t
Medical	J2777	VABYSMO	faricimab-svoa	Yes, through the Plan Pharmacy Services	VABYSMO (faricimab-svoa)	<u>VABYSMO (faricimab-svoa)</u>	MAPD Prior Authorization based on National Co
Medical	J9303	VECTIBIX	panitumumab	Yes, through the Plan Pharmacy Services	<u>VECTIBIX (panitumumab)</u>	<u>VECTIBIX (panitumumab)</u>	MAPD Prior Authorization needed outlined in t
Medical	J9041	VELCADE	bortezomib - preferred	Yes, through the Plan Pharmacy Services	<u>VELCADE (bortezomib - preferred)</u>	<u>VELCADE (bortezomib - preferred)</u>	MAPD Prior Authorization based on National Co

ior Authorization Form	MAPD
<u>umab-trbw)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mab-jsgr)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>nab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
vedotin-tftv))	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>mab-bavi)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
umab-qyyp)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ustine)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
<u>n or derivative)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
<u>mab govitecan-hziy)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>nab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
o-abbs)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
<u>ab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mzwv)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>stim-cbqv)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>ımab)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
mab-ipdl)	
nab-cdon)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>b-svoa)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
imab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
iib - preferred)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions

ns WI, IL, MO
ns WI, IL, MO.
ns WI, IL, MO
ns WI, IL, MO

	(formerly WellFirst Health)	INJ	IECTABLE MEDICINES	SEARCH TIPS:	SEARCH TIPS:		
	Updated: 05/01/2025	are covered, not covered, or not coverage review of any drug listed	ng of the most commonly prescribed drugs under the medical benefit t yet reviewed and whether a prior authorization is required. For d as not covered, please complete the Exception to Coverage form rebsite for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	t This is a large document, but you can search quickly and easily by clicking on for you to type in the name of drug you want to locate. If you do not know th few letters of th	ne correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	Q5129	VEGZELMA	bevacizumab-adcd	As of 03/01/2024: Zirabev is the preferred Bevacizumab product and doe not require prior authorization. Avastin, Alymsys, Mvasi and Vegzelma prior authorization is required through the Plan Pharmacy Services. ***Prior authorization for bevacizumab is not required when used for ophtalmological indications.*** See the ALYMSYS (bevacizumab) Policy for a list of applicable ophthalmological diagnoses.	VEGZELMA (bevicizumab-adcd)	VEGZELMA (bevicizumab-adcd)	MAPD Prior Authorization based on National Coverage Determination (NCD),
Medical	J1756	VENOFER - preferred		As of 08/01/2022: VENOFER, INFED, FERRLECIT, and FERAHEME are the preferred parenteral iron products and do not require prior authorization. INJECTAFER, MONOFERRIC, TRIFERIC, and TRIFERIC AVNU are the non-preferred parenteral iron products and prior authorization is required through the Plan Pharmacy Services with authorization.			MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J9376	VEOPOZ	pozelimab-bbfg	Yes, through the Plan Pharmacy Services	<u>VEOPOZ® (pozelimab-bbfg)</u>	<u>VEOPOZ® (pozelimab-bbfg)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J1427	VILTEPSO	viltolarsen	None. Not Covered.	VILTEPSO (vitolarsen)		
Medical	J1323	VIMIZIM	elosulfase (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Mucopolysaccharidosis IVA with authorization.	<u>VIMIZIM (elosulfase)</u>	<u>VIMIZIM (elosulfase)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J7321	VISCO-3 - non-preferred	hyaluronan or derivative	As of 08/01/2022: HYALGAN, SYNVISC, SYNVISC ONE, HYMOVIS, and TRILURON will be the preferred hyaluronic acid products and do not require prior authorization. Monovisc, Durolane, Gel-One, Euflexxa, Gelsyn-3, Visco-3, sodium hyaluronate, TriVisc, Orthovisc, Supartz FX, and GenVisc850 are the non-preferred hyaluronic acid products and prior authorization is required through the Plan Pharmacy Services. Please see Medical Policy for criteria		<u>VISCO-3 (hyaluronan or derivative)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD),
Medical	19999	VIVIMUSTA	bendamustine	Yes, through the Plan Pharmacy Services	VIVIMUSTA (bendamustine)	<u>VIVIMUSTA (bendamustine)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD),
Medical	J3385	VPRIV	velaglucerase alfa (Intravenous)	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Medical Geneticist or other prescriber specialized in the treatment of Gaucher DX with authorization.	VPRIV (velaglucerase alfa)	VPRIV (velaglucerase alfa)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J3032	VYEPTI	epinezumab-jjmr	Yes, through the Plan Pharmacy Services	<u>VYEPTI (epinezumab-jjmr)</u>	<u>VYEPTI (epinezumab-jjmr)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J3401	VYJUVEK	beremagene geperpavec-svdt	Yes, through the Plan Pharmacy Services	VYJUVEK™ (beremagene geperpavec-svdt)	VYJUVEK™ (beremagene geperpavec-svdt)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J1429	VYONDYS 53	golodirsen	None. Not Covered.	VYONDYS 53 (golodirsen)		
Medical	J9332	VYVGART	efgartigimod alfa-fcab	Yes, through the Plan Pharmacy Services. Must be prescribed by or in consultation with a neurologist.	<u>VYVGART (efgartigmoid)</u>	VYVGART (efgartigmoid)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J9999/C9399	VYLOY	zolbetuximab-clzb	Yes, through the Plan Pharmacy Services.	VYLOY (zolbetuximab-clzb)	<u>VYLOY (zolbetuximab-clzb)</u>	
Medical	J9334	VYVGART-HYTRULO	efgartigimod alfa-fcab and hyaluronidase-qvfc	Yes, through the Plan Pharmacy Services	VYVGART [®] Hytrulo (efgartigimod alfa-fcab and hyaluronidase- avfc)	VYVGART [®] Hytrulo (efgartigimod alfa-fcab and hyaluronidase-qvfc)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J9153	VYXEOS	daunorubicin and cytarabine – liposome	Yes, through the Plan Pharmacy Services	VYXEOS (daunorubicin and cytarabine – liposome)	VYXEOS (daunorubicin and cytarabine – liposome)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	Q5138	WEZLANA	ustekinumab-auub	Yes, through the Plan Pharmacy Services.	<u>WEZLANA (ustekinumab-auub)</u>	WEZLANA (ustekinumab-auub)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J3590	WYOST	denosumab	EFFECTIVE 05/01/2025. No prior authorization is required.	<u>WYOST (denosumab)</u>	<u>WYOST (denosumab)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD),
Medical	J1558	XEMBIFY (SCIG)	immune globulin	Yes, through the Plan Pharmacy Services	XEMBIFY (SCIG)	XEMBIFY (SCIG)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J0218	XENPOZYME	olipudase alfa	Yes, through the Plan Pharmacy Services.	XENPOZYME™ (olipudase alfa)_	XENPOZYME™ (olipudase alfa)_	MAPD Prior Authorization based on National Coverage Determination (NCD),
Medical	J0897	XGEVA	denosumab	EFFECTIVE 05/01/2025. No prior authorization is required.	<u>XGEVA (denosumab)</u>	XGEVA (denosumab)	MAPD Prior Authorization based on National Coverage Determination (NCD),
Medical	J2357	XOLAIR	omalizumab, 5mg	EFFECTIVE 05/01/2025. No prior authorization is required.	<u>XOLAIR (omalizumab)</u>	<u>XOLAIR (omalizumab)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Loca
Medical	J0588	XEOMIN	incobotulinumtoxinA	No prior authorization is required.	XEOMIN (incobotulinumtoxinA)		MAPD Prior Authorization based on National Coverage Determination (NCD), Loca
Medical	J3299	XIPERE	triamcinolone acetonide injectable suspension	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) an opthamalogist specialist with authorization.	XIPERE (triamcinolone acetonide injectable suspension)	XIPERE (triamcinolone acetohnide injectable suspension)	Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare B
Medical	J9228	YERVOY	ipilimumab	Yes, through the Plan Pharmacy Services	YERVOY (iplimumab)	YERVOY (ipilimumab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma
Medical	J3590	YESAFIL	aflibercept	Yes, through the Plan Pharmacy Services	<u>YESAFIL (aflibercept)</u>	YESAFIL (aflibercept)	
Medical	Q2041	YESCARTA	axicabtagene ciloleucel	Yes, through the Plan Pharmacy Services	YESCARTA (axicabtagene ciloleucel)	YESCARTA (axicabtagene ciloleucel)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Ma

Prior Authorization Form	MAPD
izumab-adcd)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nab-bbfg)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>se)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>nan or derivative)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
lamustine)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
<u>ase alfa)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nab-jjmr)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nagene geperpavec-svdt)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
gmoid)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nab-clzb)	
o (efgartigimod alfa-fcab and hyaluronidase-qvfc)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>bicin and cytarabine – liposome)</u>	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
numab-auub)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
nab)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
ipudase alfa)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
<u>ab)</u>	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions
nab)	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdictions WI, IL, MO
lone acetohnide injectable suspension)	Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals.
nab)	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
<u>pt)</u>	

Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs

ns WI, IL, MO	
ns WI, IL, MO	
ns WI, IL, MO	
ns WI, IL, MO	
ns WI, IL, MO	
ns WI, IL, MO	7

) Medica . (formerly WellFirst Health)	IN	JECTABLE MEDICINES	SEARCH TIPS:			
	Updated: 05/01/2025	are covered, not covered, or not coverage review of any drug liste	ing of the most commonly prescribed drugs under the medical benefit ot yet reviewed and whether a prior authorization is required. For ed as not covered, please complete the Exception to Coverage form website for medical submit to the Plan Pharmacy Services and for pharmacy submit to Navitus.	This is a large document, but you can search quickly and easily by clicking on t for you to type in the name of drug you want to locate. If you do not know the few letters of the	correct spelling, you can start your search by entering just the first		
Benefit	J Code	Brand Names	Generic names	Prior Authorization or Restrictions	Policy	Prior Authorization Form	
Medical	J3590	YESINTEK	ustekinumab	Yes, through the Plan Pharmacy Services	<u>YESINTEK (ustekinumab)</u>	<u>YESINTEK (ustekinumab)</u>	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	J9352	YONDELIS	trabectedin	Yes, through the Plan Pharmacy Services	YONDELIS (trabectedin)	YONDELIS (trabectedin)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	Q5101	ZARXIO	filgrastim-ayow	EFFECTIVE 01/01/2023: Nivestym and Zarxio are the preferred Filgrastim products and do not require prior authorization. Neupogen, Releuko and Granix, require prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria.		ZARXIO (filgrastim-ayow)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	J0256	ZEMAIRA/PROLASTIN-C	alpha-1-proteinase inhibitor (human)	Yes through the Plan Pharmacy Services. Restricted to an Pulmonology specialist with authorization.	ZEMAIRA/PROLASTIN-C (alpha-1-proteinase inhibitor)	ZEMAIRA/PROLASTIN-C (alpha-1-proteinase inhibitor)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	J9223	ZEPZELCA	lurbinectedin	Yes, through the Plan Pharmacy Services	ZEPZELCA (lurbinectedin)	ZEPZELCA (lurbinectedin)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	Q5120	ZIEXTENZO - preferred	pegfligrastim-bmez	EFFECTIVE 01/01/2024: FULPHILA and NYVEPRIA are the preferred Pegfilgrastim products and do not require prior authorization. Must have a failed trial of ZIEXTENZO AND FULPHILA before coverage of Neulasta. UDENCYA, FYLNETRA, STIMUFEND and ZIEXTENZO require a prior authorization through the Plan Pharmacy Services. Please see Medical Policy for criteria	<u>ZIEXTENZO (pegfligrastim-bmez)</u>	<u>ZIEXTENZO (pegfilgrastim-bmez)</u>	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	Q5118	ZIRABEV - preferred	bevacizumab-bvzr	As of 03/01/2024: Zirabev is the preferred Bevacizumab product and does not require prior authorization. Avastin, Alymsys, Mvasi and Vegzelma prior authorization is required through the Plan Pharmacy Services. ***Prior authorization for bevacizumab is not required when used for ophtalmological indications.*** See the ALYMSYS (bevacizumab) Policy for a list of applicable ophthalmological diagnoses.	ZIRABEV (bevicizumab-bvzr)	ZIRABEV (bevacizumab-bvzr)	MAPD Prior Authorization based on National Coverage Determina
Medical	19999	ZIIHERA	zanidatamab-hrii	Yes, through the Plan Pharmacy Services	ZIIHERA (zanidatamab-hrii)	<u>ZIIHERA (zanidatamab-hrii)</u>	
Medical	C9399, J3590	ZOLGENSMA	onasemnogene abeparvovic-xioi	Yes, through the Plan Pharmacy Services. Restricted to (in at least consultation with) a Neurologist with expertise in the diagnosis of Spinal Muscular Atrophy (SMA) with authorization.	ZOLGENSMA (onasemnogene abeparvovec-xioi)	ZOLGENSMA (onasemnogene abeparvovec)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	J9359	ZYNLONTA	loncastuximab tesirine	Yes, through the Plan Pharmacy Services	ZYNLONTA (loncastuximab)	ZYNLONTA (loncastuximab tesirine)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	J3393	ZYNTEGLO	betibeglogene autotemcel	Yes, through the Plan Pharmacy Services	ZYNTEGLO [®] (betibeglogene autotemcel)	ZYNTEGLO® (betibeglogene autotemcel)	MAPD Prior Authorization needed outlined in the Medicare Bene
Medical	J9345	ZYNYZ	retifanlimab-dlwr	Yes, through the Plan Pharmacy Services	ZYNYZ (retifanlimab-dlwr)	ZYNYZ (retifanlimab-dlwr)	MAPD Prior Authorization needed outlined in the Medicare Bene
	Notes:						
			on the WellFirst Health drug formulary. The on-line formulary	There are claim specific edits for many of these drugs. The edits limit the uses of these drugs to approved indications and dosages. In addition, WellFirst Health has payment restrictions consistent with WellFirst Health Medical or Drug Policies.		The Health Plan will not cover U.S. Food and Drug Administration (FDA) approved drugs that are new to the market until the Pharmacy and Therapeutics (P&T) Committee formally reviews and grants approval, within a maximum timeframe of 1 year from FDA approval. If a provider believes that use of a new drug is medically necessary prior to P&T Committee approval, they may submit an exception to coverage form request.	
			Ido not have a Loode assigned by the FLIA New drugs may take	Any drug submitted under either J3590 or J3490 with a cost of \$750 or greater will be reviewed post-claim by WellFirst Health.	It is recommended that any use of the miscellaneous codes be pre-approved ahead of time through WellFirst Health Utilization Management, especially for off-label uses from FDA indications.	Pharmacy Drug Exception to Coverage Form - IL Pharmacy Drug Exception to Coverage Form - MO	Medical Injectable Drug Exception to Coverage Form - IL Medical Injectable Drug Exception to Coverage Form - MO
L	1		1	1	1	1	

	MAPD
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization based on National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) for guidance where applicable for Jurisdiction
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
	MAPD Prior Authorization needed outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals for drugs
/	
•	

	_
s WI, IL, MO	
	_